Category: Newsletter Articles & Posts

ICARE Social Media Post November 2024

Breast Cancer After Ovarian Cancer in BRCA Carriers

As highlighted in the latest ICARE newsletter, a recent study evaluated breast cancer risks after ovarian cancer in BRCA1 & BRCA2 carriers. ๐Ÿ” After chemotherapy for ovarian cancer: ๐Ÿ“Š Incidence rates were: ๐Ÿ“ˆ What does this mean? Learn more at: https://tinyurl.com/yc8de3py Reference: Evans, et al. Genet Med. 2024;26(9):101172. PMID: 38847192. We also encourage you to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111924/

ICARE Social Media Post November 2024

Germline Mutations in Renal Cell Cancer Patients

A new study among patients with renal cell carcinoma reported a higher chance of finding a mutation in an inherited cancer-related gene in those with: Read the full article to learn more at:https://pubmed.ncbi.nlm.nih.gov/38127826/ Reference: Nguyen, et al. JCO Precis Oncol. 2023;7: e2300168. PMID: 38127826.

Permanent link to this article: https://inheritedcancer.net/post111424/

ICARE Social Media Post November 2024

BRCA Carriers with Breast Cancer: Trial to Compare PARP Inhibitors to Chemotherapy

As highlighted in the latest ICARE newsletter, a recent trial among BRCA1/2 carriers with breast cancer comparing PARP inhibitors to standard chemotherapy (Treatment of Physician’s Choice – TPC) found that after 25.7 months of follow up: Overall survival in each group was: The % alive at 3 years was: Patients who received Olaparib for first …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111224/

ICARE Social Media Post November 2024

Reduced Penetrance BRCA1/2 Pathogenic Variants

Check out our recently published study that brings attention to “reduced penetrance” BRCA1 and BRCA2 (BRCA) pathogenic variants, which impart LOWER breast cancer risks than ‘typical’ BRCA mutations. Specifically, lifetime breast cancer risks for these reduced penetrance BRCA variants are 20-30% which is similar to that seen in moderate penetrance breast cancer genes (e.g., CHEK2 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111124/

ICARE Social Media Post November 2024

NCCN Breast, Ovarian, Pancreatic, and Prostate Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate Cancer guidelines on November 7th, 2024 (Version 2.2025) You read that right – they have now added “prostate” to the name as well as the relevant content! Prostate cancer specific testing and risk management information is now centralized …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110824/

ICARE Social Media Post November 2024

NCCN Guideline Updates: CDKN2A

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024 (Version 1.2025), which included the following CDKN2A updates โคธ The CDKN2A gene produces two isoforms, both of which are tumor suppressors:โžก๏ธ p16INK4A and p14ARF For individuals with both of these isoforms, recommend:โžก๏ธ Skin exams …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110724/

ICARE Social Media Post November 2024

NCCN BOP Guideline Update #10: BRCA2 Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN added consideration of pancreatic cancer screening for BRCA2 carriers as outlined in PANC-A 1 of 2 (Page 52). To read more, you can check out the full guidelines by creating …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110224/

ICARE Social Media Post November 2024

May 2025 BRCA Symposium

Calling all healthcare providers and researchers! ๐Ÿงฌ Join us at BRCA 2025 – the 10th International Symposium on Hereditary Breast and Ovarian Cancer, taking place from May 6th-9th, 2025 in Montrรฉal, Quรฉbec, Canada. We’re celebrating 30 years since the discovery of the BRCA genes and 20 years of bringing the world’s top minds together to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110124/

ICARE Social Media Post October 2024

Personalized Screening Recommendations for CHEK2 Carriers

A recent editorial highlights the value of personalized screening recommendations for CHEK2 carriersโ–ช๏ธ Notably, three common low-risk mutations (p.I157T, p.S428F, and p.T476M) impart a breast cancer risk of less than 1.4 foldโ–ช๏ธ This level of risk does not warrant high-risk breast screening or other heightened care Read the full article to learn more at: https://www.oncotarget.com/article/28604/pdf/ …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post103124/

ICARE Social Media Post October 2024

Men’s Stories About Hereditary Cancer

In recognition of Breast Cancer Awareness Month, we are excited to share the newly released “Men’s Stories About Hereditary Cancer”. Read the full piece to hear how BRCA gene mutations affect men and steps you can take to learn about and manage your cancer risks โคธhttps://tinyurl.com/mensstorieshereditarycancer

Permanent link to this article: https://inheritedcancer.net/post102824/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #9: Pancreatic Cancer Screening Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. An important update includes consideration of pancreatic cancer screening for ATM and BRCA2 carriers even in the absence of family history as outlined in PANC-A 1 of 2 (PAGE 52). To read more, you …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102824_1/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #8: CHEK2 Bi-allelic Mutations

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN outlines emerging data regarding breast cancer risks for bi-allelic CHEK2 mutations (i.e., mutations in both copies of the gene) as outlined in GENE-A (Page 38) โคธ To read more, you …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102424/

ICARE Social Media Post October 2024

Lack of Genetic Counseling and Testing Among Female Cancer Survivors

A recent study among women with early-stage breast cancer revealed that many female cancer survivors who meet guidelines for genetic counseling and testing for inherited cancer do not receive it. These findings underscore the need for better access to genetic counseling and testing to support patients and their families. Learn more at: https://bit.ly/3MkeM2o Reference: Katz, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102324/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #7: CHEK2: Ile157Thr and Ser428Phe

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN outlines the following for the CHEK2 Ile157Thr and Ser428Phe variants as outlined in GENE-A (Page 38) โคธ To read more, you can check out the full guidelines by creating a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102324_1/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 – #2 EPCAM Updates

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN revised information about EPCAM gene (which has usually been lumped together with MSH2) as follows โคธ You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102224/

ICARE Social Media Post October 2024

Inherited Breast Cancers in Men

In honor of Breast Cancer Awareness month, we wanted to spread awareness about inherited breast cancer risks among men. Did you know that men with a BRCA2 mutation have about a 7% lifetime risk of breast cancer and those with a BRCA1 or PALB2 mutation have about a 1% lifetime risk of breast cancer? Thus, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102124/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #6: BRCA1 R1699Q

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some BRCA1 updates as outlined in GENE-A (Page 36) include โคธ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post101924/

ICARE Social Media Post October 2024

November 2024 BRCA Hybrid Event Post – Patients & Public (Nov 5th) First post

Are you or someone you love affected by a BRCA gene mutation ๐Ÿงฌ ? This event is for you! On November 5th, Women’s College Hospital will be hosting a hybrid event entitled, BRCA: 30 Years, Discovery to Impact, to celebrate 30 years since the groundbreaking discovery of the BRCA1 and BRCA2 genes. Learn from leading …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101724/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #5: ATM Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these new guidelines, there were several updates for ATM carriers, including adding colorectal cancer risk as outlined in GENE-A (Page 35) and consideration of pancreatic cancer screening as outlined in PANC-A 1 of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101724_1/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #4: Ovarian Cancer Risks and Management Updates

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some updates include revisions to ovarian cancer risks and management including โคธ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post101224/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024 = #1 Testing Considerations

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. In these updated guidelines, NCCN added the following to testing being considered โคธPersonal history of colorectal or endometrial cancer at or older than age 50, and: You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101524/

ICARE Social Media Post October 2024

Pancreatic Cancer Screening in High-Risk Patients

A recent study among high-risk patients found that pancreatic cancer screening through endoscopic ultrasound and/or MRI-based tests led to detection of smaller and earlier-stage cancers and overall, seemed to result in longer survival. Patients with an inherited gene mutation that predisposes to pancreatic cancer and/or a family history of pancreatic cancer were considered to be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101024/

ICARE Social Media Post October 2024

Double Mastectomy Not Linked To Survival Advantage

A recent study found that in women with breast cancer, double mastectomy did NOT lead to longer survival. This is very important information for women to know as they make decisions about breast cancer surgery. Read the full article to learn more at: https://bit.ly/47a5O1b Reference: Giannakeas, et al. JAMA Oncol. 2024:e242212. PMID: 39052262.

Permanent link to this article: https://inheritedcancer.net/post100924_1/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update V2.2024

The National Comprehensive Cancer Network (NCCN) released updated Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on October 3rd, 2024. Updates include โคธ Added the following to testing being considered: Personal history of colorectal or endometrial cancer at or older than age 50, and: Revised information about EPCAM gene (which has usually been …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100824/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #3: Genetic Testing in Breast Cancer Patients Age 65 and Below

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updated guidelines, NCCN indicates testing criteria for high-penetrance breast cancer susceptibility genes should be considered for those with a personal history of breast cancer โ‰ค age 65 (used to be < age …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100824_1/

ICARE Social Media Post October 2024

BRCA2: Male Breast Cancer Risks

Did you know that men can get breast cancer too? In fact, Beyonce’s father, Matthew Knowles, was diagnosed with breast cancer in October 2019 and was found to have a BRCA2 mutation. Matthew’s children have a 50/50 chance of inheriting his BRCA2 mutation. Men with an inherited BRCA2 mutation are at an increased risk for …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100724/

ICARE Social Media Post October 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 5

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. An important update includes the revision of CHEK2 estimated absolute colon cancer risk to “NO INCREASED RISK”; thus, general population screening is appropriate for these individuals. You can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/100624-2/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #2: Testing Unaffected Family Members

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updates, NCCN clarified that it is appropriate to test unaffected (not best testable) family members when they meet testing criteria. To read more, you can check out the full guidelines by creating …

Continue reading

Permanent link to this article: https://inheritedcancer.net/100424_1/

ICARE Social Media Post October 2024

NCCN BOP Guideline Update #1: Point-of-Care Testing

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. In these updated guidelines, the minimal components that should be discussed during point-of-care testing are outlined (found in EVAL-A 10 of 11; Page 17). To read more, you can check out the full guidelines …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100324/

ICARE Newsletter Fall 2024

Community Spotlight: The Patient and the Researcher Shares Her Uncertain Future and Lessons Sheโ€™s Learned

By Marleah Dean Kruzel, PhD, BRCA2 Previvor When I was eight years old, my mother found a lump in her breast โ€“ barely noticeable. For a few years, I watched her undergo chemotherapy, radiation, and a prophylactic mastectomy and reconstruction. Since then, my maternal aunt and grandmother also fought breast cancer, and we learned my …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-community-spotlight-the-patient-and-the-researcher-shares-her-uncertain-future-and-lessons-shes-learned/

ICARE Newsletter Fall 2024

Double Mastectomy Not Linked to Survival Advantage

A recent study found that in females with unilateral breast cancer (meaning breast cancer on one side) who decided to have a double mastectomy had similar mortality rates to those treated with lumpectomy or unilateral mastectomy (meaning double mastectomy did NOT lead to longer survival). Findings showed that while bilateral mastectomy greatly lowered the risk …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-double-mastectomy-not-linked-to-survival-advantage/

ICARE Newsletter Fall 2024

New Study to Evaluate Pancreatic Cancer Screening

A recent study among high-risk patients found that pancreatic cancer screening through endoscopic ultrasound and/or MRI-based tests led to detection of smaller and earlier-stage cancers, and overall, seemed to result in longer survival. Patients with an inherited gene mutation that predisposes to pancreatic cancer and/or a family history of pancreatic cancer were considered to be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-new-study-to-evaluate-pancreatic-cancer-screening/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers: Treatment Advances

Among BRCA1/2 carriers with advanced breast cancer, PARP inhibitors showed some activity even in patients with platinum resistant/unresponsive disease. However, the optimal delivery of platinum agents and PARP inhibitors was not clear.1 In another study of BRCA1/2 carriers with breast cancer (OlympiAD Trial), PARP inhibitors were compared to chemotherapy Treatment of Physicianโ€™s Choice (TPC), with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-treatment-advances/

ICARE Newsletter Fall 2024

American Society of Clinical Oncology (ASCO) Guideline Update: Selecting Genetic Tests in Patients with Various Cancers

What elements are most important in the collection of family history? When and how to use multigene panel testing when indicated? Which genes should be tested based on cancer type? Among patients with tumor testing, who should be offered germline testing? For a full list of recommendations in this guideline, the article is available at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-american-society-of-clinical-oncology-asco-guideline-update-selecting-genetic-tests-in-patients-with-various-cancers/

ICARE Newsletter Fall 2024

Breast Cancer After Ovarian Cancer in BRCA1/2 Carriers

A recently published study reported that among females with ovarian cancer who received chemotherapy, their risk for breast cancer was lower for the next 5 years. Specifically, incidence rates were lower at 2 years (1.18%) and between 2 to 5 years (1.13%); however, incidence rates rose thereafter for BRCA1 carriers (>4% annually post 10 years). This study …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-breast-cancer-after-ovarian-cancer-in-brca1-2-carriers/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers and Pregnancy-Related Risk

A recent study reported that pregnancy after breast cancer was safe for both mother and baby.1 Specifically, the researchers found that pregnancy after breast cancer was not associated with adverse maternal prognosis or fetal outcomes. Another study reported that breast cancer after pregnancy could be associated with poorer outcomes. Specifically, breast cancer diagnosed within 10 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-and-pregnancy-related-ris/

ICARE Newsletter Fall 2024

BRCA1/2 Carriers: Risk of Peritoneal Cancer After Bilateral Oophorectomy

A recent study among BRCA1 and BRCA2 carriers, which included ICARE participants, found that the risk for peritoneal cancer following a preventive bilateral oophorectomy was higher among BRCA1 carriers than BRCA2 carriers. Specifically, among 6310 females, the annual risk of peritoneal cancer was 0.14% for BRCA1 carriers and 0.06% for BRCA2 carriers, and the 20-year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca1-2-carriers-risk-of-peritoneal-cancer-after-bilateral-oophorectomy/

ICARE Newsletter Fall 2024

Risk of Melanoma in BRCA1/2 Carriers

Over the last few years, there has been mixed information about the risk of melanoma in BRCA1/2 carriers โ€“ while earlier studies had suggested an association,1,2 other studies showed no association.3,4 Thus, based on current evidence, it is unclear if BRCA1 and/or BRCA2 pathogenic variants increase melanoma risk based on the current evidence.5,6 However, more recently, a study, which …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-risk-of-melanoma-in-brca1-2-carriers/

ICARE Newsletter Fall 2024

BRCA2-Associated Prostate Cancer

A new study found that males with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Custodio-Cabello, et al. Urol Oncol. 2024;42(10):331.e13-331.e24. PMID: 38926076. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-brca2-associated-prostate-cancer/

ICARE Newsletter Fall 2024

Risks of Cancer in Individuals with TWO CHEK2 Mutations (called โ€œBi-Allelicโ€ Mutations)

A new study found that risks may be higher for multiple types of cancer, including breast cancer, in both females and males who have two CHEK2 mutations: Additionally, findings showed that the type of mutation may be important to guide level of risk (e.g., truncating 1100delC homozygotes being at a higher risk than compound heterozygotes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-risks-of-cancer-in-individuals-with-two-chek2-mutations-called-bi-allelic-mutations/

ICARE Newsletter Fall 2024

National Comprehensive Cancer Network (NCCN) Guideline Updates

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer โ€“ Released September 11th, 2024 (V1.2025) Check out the full guidelines by creating a FREE account at www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Testing Updates: Gene Updates: Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric Cancer โ€“ Released August 8th, 2024 (V1.2024) Check out the full guidelines by creating a FREE account at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2024-national-comprehensive-cancer-network-nccn-guideline-updates/

ICARE Social Media Post September 2024

BRCA2-Associated Prostate Cancer

A new study found that men with a BRCA2 mutation and metastatic hormone-sensitive prostate cancer face poorer outcomes. BRCA2 carriers were also found to have a higher risk of progression to castration-resistant prostate cancer. These findings highlight the importance of evaluating germline mutations among prostate cancer patients. Learn more by reading the full article at: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post93024/

ICARE Social Media Post September 2024

NCCN CEG Guideline Update #3: Use of HRT following premature surgical menopause

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include use of hormone replacement treatment following premature surgical menopause from risk-reducing oophorectomy. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/poat92524/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 3

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include gynecologic risk and preventive surgery considerations for MLH1, MSH6, MSH2, and PMS2 carriers. You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91824/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update – VERSION 2

The National Comprehensive Cancer Network (NCCN) released the new Genetic/Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include โคธ You can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf

Permanent link to this article: https://inheritedcancer.net/post91424/

ICARE Social Media Post September 2024

NCCN Breast, Ovarian, and Pancreatic Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer guidelines on September 11th, 2024. Some updates include โคธ To read more, you can check out the full guidelines by creating a FREE account at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91224/

ICARE Social Media Post September 2024

NCCN Colorectal, Endometrial, and Gastric Cancer Guidelines Update

The National Comprehensive Cancer Network (NCCN) released the new Genetic Familial High-Risk Assessment Colorectal, Endometrial, and Gastric Cancer guidelines on August 8th, 2024. Updates include โคธโ€ข Endometrial cancer recommendations included throughoutโ€ข Hereditary Diffuse Gastric Cancer section added (HGAST-1)โ€ข Gynecologic risk and preventive surgery considerations for those with Lynch Syndromeโ€ข Use of hormone replacement treatment following …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90324/

ICARE Social Media Post August 2024

ICARE Overview Video

Learn more about the Inherited Cancer Registry (ICARE) by watching an exciting presentation by student researcher, Reagan Sellers, who provides information about the history of ICARE, what being an ICARE participant entails, our various education and engagement efforts, and the focused research studies being conducted through ICARE. Check out the full video on our YouTube …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82824/

ICARE Social Media Post August 2024

BRCA1/2 carriers: Melanoma Risk?

A new study in which ICARE participants were included reported that compared to 1.5% in the general population, the risk of melanoma may be slightly elevated: in BRCA1/2 carriers:โ—‹ BRCA1: 2.5%โ—‹ BRCA2: 2.3% Read the full article to learn more at: https://tinyurl.com/ye2xxfru Reference: Narod et al. Hered Cancer Clin Pract. 2024;22(1):7. PMID: 38741145.

Permanent link to this article: https://inheritedcancer.net/post82624/

ICARE Social Media Post August 2024

Peritoneal Cancer After Oophorectomy in BRCA1/2 Carriers

A recent study among BRCA1 and BRCA2 carriers, which included ICARE participants, found that the risk for peritoneal cancer following a preventive bilateral oophorectomy was higher among BRCA1 carriers than BRCA2 carriers. Specifically, among 6310 women, the annual risk of peritoneal cancer was 0.14% for BRCA1 carriers and 0.06% for BRCA2 carriers, and the 20-year …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82524/

ICARE Social Media Post August 2024

How to Access NCCN Guidelines

Unlock valuable resources for your health journey! ๐ŸŒŸ The National Comprehensive Cancer Network (NCCN) guides clinical practice by providing free access to their guidelines that are available to both patients and healthcare providers. To access the most recent version of cancer-related guidelines that are updated at least annually, create a free username and password at …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82024/

ICARE Social Media Post August 2024

FDA Approved a Blood Test for Colorectal Cancer Screening

Breaking News: The FDA recently approved a blood test for colorectal cancer screening! ๐Ÿ” What does this mean? โญ Bottom Line: Learn more at: https://www.nejm.org/doi/full/10.1056/NEJMoa2304714 Reference: Chung, et al. N Engl J Med. 2024;390(11):973-983: PMID: 38477985.

Permanent link to this article: https://inheritedcancer.net/post80824/

ICARE Social Media Post August 2024

Comparing Cancer Risk Management between Females with Truncating CHEK2 1100delC versus Missense CHEK2 I157T Variants

In a recent study based on ICARE participants, we compared cancer risk management between those with CHEK2 1100delC (which leads to moderate breast cancer risk, generally more than 20% lifetime risk) versus I157T (which is a low penetrance mutation, with breast cancer risks of less than 20%) ๐Ÿ‘ฉโ€๐Ÿ”ฌ Of the 150 CHEK2 carriers, there were …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post80524/

ICARE Social Media Post July 2024

Genetics Role in Identifying Lower Breast Cancer Risk

A new study of 25,591 women found: Based on genetic risk, identifying individuals at: This study challenges a one-size-fits all mammogram screening approach. This approach could possibly reduce rising healthcare costs by reallocating resources and lower unnecessary anxiety that comes with frequent screenings, and even prevent unnecessary procedures. Read the full article to learn more …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72924/

ICARE Social Media Post July 2024

New Study in POT1 Carriers

In recognition of Sarcoma Awareness Month, a new study found that POT1 mutations are associated with an increased risk for melanoma and a wider variety of different sarcomas than previously described. Specifically, the study showed significant raised risks of around 7-fold for both sarcoma and melanoma. This included many different types of sarcomas, including: Learn …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72824/

ICARE Social Media Post July 2024

New Genes Raise Breast Cancer Risks Identified in Study of African Women

A new study, which included ICARE-related efforts through including BEST study participants:โ–ช๏ธ Identified 12 breast cancer genes that may help to predict breast cancer riskโ–ช๏ธ Included more than 40,000 women of African ancestry, almost half of which had breast cancer Why is studying individuals from diverse ancestral backgrounds important?โ–ช๏ธ Refine risks across diverse populationsโ–ช๏ธ A …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72524/

ICARE Social Media Post June 2024

ICARE Post #3 – PALB2 Genomics Study Post

If you have a history of breast cancer and a mutation in the PALB2 gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in PALB2 carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post71124/

ICARE Social Media Post June 2024

ICARE Post #3 – CHEK2 Genomics Study Post

If you have a history of breast cancer and a mutation in the CHEK2 gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in CHEK2 carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post7052024/

ICARE Social Media Post June 2024

ICARE Post #3 – ATM Genomics Study Post

If you have a history of breast cancer and a mutation in the ATM gene, you may be eligible to contribute to tumor genomics studies to help better understand inherited breast cancer in ATM carriers. Through the Inherited Cancer Registry (ICARE), we are studying: With your help, we hope that one day our research may …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post62324/

ICARE Social Media Post June 2024

Breast Cancer Patients with BRCA Variants Diagnosed Within 10 Years Postpartum at Higher Mortality Risk

A new study reported that among BRCA carriers, breast cancer diagnosed within 10 years of having a child was associated with a higher risk of mortality, especially in BRCA1 carriers. This information could be important for genetic counseling, prevention, and treatment strategies in BRCA carriers. Learn more by reading the full article at: https://bit.ly/3wHyAIz Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60624/

ICARE Social Media Post June 2024

Pregnancy after Breast Cancer: BRCA carriers

A new study reported that pregnancy after breast cancer was not associated with adverse maternal prognosis or fetal outcomes. These findings suggest that pregnancy after breast cancer is safe for both mother and baby. Read the full article at: https://bit.ly/3wcoa3xReference: Newman, et al. JAMA Surg. 2024. Online ahead of print. PMID: 38536201. Follow us to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60324/

ICARE Social Media Post May 2024

New ASCO Guideline: Selection of Germline Testing Panels in Patients With Cancer

The American Society of Clinical Oncology (ASCO) just released new guidelines for the selection of germline genetic testing panels in patients with cancer. Items addressed include โคธ What elements are most important in the collection of family history?๐Ÿงฌ Details of cancers in first- and second-degree relatives and the patient’s ethnicity. When and how to use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52124/

ICARE Social Media Post May 2024

AACR Cancer Disparities Progress Report 2024

The American Association for Cancer Research (AACR) just released a Cancer Disparities Progress Report on May 15th, which includes highlights on inherited cancers! On Page 163, this report discusses policies to address disparities in screening and surveillance for hereditary cancer syndromes. It also highlights an electronic support tool, called MyLynch, that can be used to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post5172024/

ICARE Social Media Post May 2024

CHEK2: Bi-Allelic Mutations

Do you know the cancer risks for individuals with CHEK2 bi-allelic mutations (i.e., those with TWO CHEK2 mutations)? A new study found that risks may be higher for multiple types of cancer, including breast cancer, in both females and males โคธโ–ช๏ธ Females more frequently developed 2 or more cancers at younger agesโ–ช๏ธ Males more frequently …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50324/

ICARE Social Media Post April 2024

YouTube Channel

ย 

Curious about inherited cancer and the latest breakthroughs? Look no further than the ICARE YouTube channel! ๐ŸŽฅ Join genetics experts as they dive into discussions on important topics like updates to NCCN cancer risk management guidelines and insights into specific inherited cancer genes. ๐Ÿ’ก Don’t miss out on some of our top-viewed videos covering management …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42824/

ICARE Newsletter Spring 2024

Inherited Risk in Patients with Pancreatic Acinar Cell Carcinoma

In a study of a rare type of pancreatic cancer, called pancreatic acinar cell cancer (PACC), over one third (36.7%) of a total of 49 patients with PACC had a mutation in an inherited cancer gene. The most commonly mutated gene was BRCA2 (12), and other genes included BRCA1 (1), PALB2 (2), ATM (2), and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-inherited-risk-in-patients-with-pancreatic-acinar-cell-carcinoma/

ICARE Newsletter Spring 2024

BRCA-Associated Prostate Cancer Treatment Updates

New studies to guide treatment strategies in men with prostate cancer and a BRCA mutation were recently published. Specifically, a recent study suggested that platinum-based chemotherapy may be as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer.1 The study sheds light on treatment options for advanced prostate cancer patients. More recently, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-brca-associated-prostate-cancer-treatment-updates/

ICARE Newsletter Spring 2024

Ask the Expert

This question was addressed by Ronald D. Alvarez, MD, MBA, Professor and Chairman of the Department of Obstetrics and Gynecology at the Vanderbilt University Medical Center in Nashville, Tennessee. He is also the current vice chair of the National Comprehensive Cancer Network (NCCN) Ovarian Cancer Treatment Guidelines and has served in multiple leadership roles in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-ask-the-expert/

ICARE Newsletter Spring 2024

How Well Do Cancer Risk Management strategies Work Among BRCA Carriers

Several important studies were published recently on the effectiveness of risk management strategies in BRCA carriers. Specifically, a recently published study in which ICARE participants were included suggested that preventive bilateral mastectomy for BRCA carriers greatly reduced the risk of developing breast cancer by 80%.1 Additionally, study findings showed that after preventive mastectomy, the chance …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-how-well-do-cancer-risk-management-strategies-work-among-brca-carriers/

ICARE Newsletter Spring 2024

Aerobic Exercise May Reduce Risk of Colorectal Cancer in Patients with Lynch Syndrome

A new research study among individuals with Lynch Syndrome reported that regular and intense aerobic exercise may lower the risk of colorectal cancer by improving the immune system’s ability to detect and remove potentially harmful cells. Specifically, the researchers enrolled 21 patients with Lynch Syndrome either to an 1) exercise group (45 minute cycling classes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-aerobic-exercise-may-reduce-risk-of-colorectal-cancer-in-patients-with-lynch-syndrome/

ICARE Newsletter Spring 2024

New Guidelines Released Through ASCO-Society of Oncology; Germline Testing in Patients with Breast Center

In January 2024, the American Society of Clinical Oncology (ASCO) in conjunction with the Society of Surgical Oncology released new guidelines for germline testing in patients with breast cancer, which include the following:  For a full list of recommendations in this guideline, the article is available at: https://ascopubs.org/doi/10.1200/JCO.23.02225 Bedrosian, et al. J Clin Oncol. 2024;42(5):584-604. PMID:38175972. Social …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-new-guidelines-released-through-asco-society-of-oncology-germline-testing-in-patients-with-breast-center/

ICARE Newsletter Spring 2024

National Comprehensive Cancer Network (NCCN) Guideline Updates

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Cancer โ€“ Released February 12th, 2024 (V3.2024) Check out the full guidelines by creating a FREE account at www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf Contralateral breast cancer risks in these updated guidelines: Expanded guidance about gynecologic cancers in BRCA1/2 carriers: Some highlights related to HRT include: Genetic/Familial High-Risk Assessment: Colorectal Cancer โ€“ Released …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2024-national-comprehensive-cancer-network-nccn-guideline-updates/

ICARE Social Media Post March 2024

ย Risk Management Strategies for Womenย with BRCA1/2

ย ย 

Two new research studies that ๐—ถ๐—ป๐—ฐ๐—น๐˜‚๐—ฑ๐—ฒ๐—ฑ ๐—œ๐—–๐—”๐—ฅ๐—˜ ๐—ฝ๐—ฎ๐—ฟ๐˜๐—ถ๐—ฐ๐—ถ๐—ฝ๐—ฎ๐—ป๐˜๐˜€ showed that risk of death is lowered among BRCA1/2 carriers with 1) MRI screening for breast cancer and 2) removal of both ovaries and fallopian tubes. ๐Ÿ’ก In the first study, MRI screening greatly lowered the risk of death from breast cancer (hazard ratio of 0.23) with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post3524/

ICARE Social Media Post February 2024

Risk-reducing mastectomy and breast cancer mortality in women with BRCA1/BRCA2

ย 

๐Ÿ”ฌ Exciting news! A recent study, which included ICARE participants, suggests the life-saving potential of preventive mastectomy for BRCA1 and BRCA2 carriers. ๐Ÿ’ช This procedure significantly reduces the risk of developing breast cancer and may even decrease the risk of breast cancer-related mortality. The study found that after preventive mastectomy, the chance of dying from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22724/

PARP Inhibitor (Olaparib) in men with BRCA mutations and prostate cancer

A recent study found that Olaparib (Lynparza) improved survival outcomes among men with BRCA1/2 mutations and metastatic castration-resistant prostate cancer, regardless of whether the mutation was germline or somatic. This underscores the potential of targeted therapies in improving outcomes for those with inherited cancer gene mutations. Learn more at: https://ascopubs.org/doi/10.1200/JCO.23.00339 Reference: Mateo, et al. J …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post22024/

ICARE Social Media Post February 2024

ย Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #1ย 

ย 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include adding contralateral breast cancer risks for BRCA1, BRCA2, PALB2, CHEK2, and other genes to the GENE-A (Cancer Risk Management) table ๐Ÿงฌ You can check out the full guidelines by creating a FREE account …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21324/

ICARE Social Media Post February 2024 ย Updates to NCCN Guidelines: Genetic/Familial Breast, Ovarian, and Pancreatic Post #2ย 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on February 12th, 2024! Updates include expanded guidance about gynecologic cancers in BRCA1 and BRCA2, including:โœ“ Reproductive considerationsโœ“ Non-surgical and surgical risk reductionโœ“ Salpingectomyโœ“ Hysterectomy considerationsโœ“ HRT after risk-reducing removal of the ovaries You can check out the full …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21324_2/

ICARE Social Media Post February 2024

ย Germline EGFR Mutations and Familial Lung Cancerย 

ย ย ย 

As featured in our Fall 2023 newsletter, inherited T790M EGFR mutations lead to a higher risk of lung cancer and are more common in the Southeast United States due to a ‘founder effect’. A study, in which our fellow Vanderbilt colleagues contributed, among individuals with this inherited cancer gene mutation found that more than half …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21224/

ICARE Social Media Post January 2024

Hereditary Cancer Genetic Testing Educational Video

ย 

Want to learn more about genetic testing for inherited cancer? We use patient stories to give information about testing, its possible value to individuals and their family, and ways to access resources to learn more about getting tested. Check out the video here: http://tinyurl.com/genetictestingvideo To get free personalized information about hereditary cancer risk and testing, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11724/

ICARE Social Media Post January 2023

Colon Adenomas in Lynch Syndrome

New research reveals that individuals under the age of 50 with Lynch Syndrome often develop small, flat adenomas, particularly in the right (proximal) colon. This finding emphasizes the importance of rigorous screening, with a special focus on the proximal colon, among these young Lynch Syndrome patients ๐Ÿฉบ๐Ÿ” Learn more at: https://www.dldjournalonline.com/article/S1590-8658(23)00946-5/fulltext Reference: Alric, et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11024/

ICARE Social Media Post January 2023

New ASCO Germline Testing in Patients With Breast Cancer Guidelines

The American Society of Clinical Oncology (ASCO) just released new guidelines for germline testing in patients with breast cancer, which include the following:๐Ÿงฌ BRCA1/2 testing should be offered to ALL patients diagnosed with breast cancer at or below age 65๐Ÿงฌ Testing for other hereditary cancer genes should also be offered based on personal and family …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post10524/

ICARE Social Media Post January 2023

BRCA/Prostate Cancer/Treatment

A recent study suggests that Platinum Chemotherapy is as effective as PARP inhibitors for individuals with BRCA-positive metastatic castration-resistant prostate cancer. The study sheds light on treatment options for advanced prostate cancer patients ๐Ÿฉบโœจ Learn more at: http://tinyurl.com/3vs2mk8f Reference: Fazekas, et al. Eur Urol Oncol. 2023: S2588-9311(23)00174-8. PMID: 37722977.

Permanent link to this article: https://inheritedcancer.net/post10324/

ICARE Social Media Post December 2023

BRCA1/2 carriers with Risk Reducing Salpingo-oophorectomy

A study among BRCA1/2 carriers who underwent a risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) found that the risk of peritoneal cancer increases if serous tubal intraepithelial carcinoma (STIC) is present – specifically, peritoneal cancer risk was 10.5% with STIC versus 0.3% without STIC at 5 years and 27.5% with STIC versus …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121923/

ICARE Social Media Post December 2023

BRCA1/2: removing both ovaries and tubes to lower risks

A recent study among nearly 500 BRCA1/2 carriers who underwent breast cancer surgery found that survival was higher in those who chose preventive removal of their ovaries and fallopian tubes (in order to reduce cancer risks) compared to those who did not, particularly in BRCA1 carriers. Learn more at: https://tinyurl.com/5hdx6ytv Reference: Martelli, et al. JAMA …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post121323/

ICARE Social Media Post December 2023

Tamoxifen and Breast Cancer Risk in BRCA Mutations

In a recent study among female BRCA1/2 carriers, including ICARE participants, researchers explored the impact of using tamoxifen and/or raloxifene on breast cancer risk. ๐Ÿ‘ฉโ€๐Ÿ”ฌ After almost 7 years of follow-up, only 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% of those in the non-user group. These findings …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120523/

ICARE Social Media Post November 2023

Aerobic Exercise May Be Effective At Reducing Risk Of Colorectal Cancer In Patients With Lynch Syndrome

New research suggests regular, intense aerobic exercise may lower colorectal cancer risk in Lynch Syndrome patients ๐Ÿƒโ€โ™‚๏ธ๐Ÿงฌ Learn more at: https://tinyurl.com/2s44828h Reference: Deng, et al. Clin Cancer Res. 2023; 29(21): 4361-4372. PMID: 37724990.

Permanent link to this article: https://inheritedcancer.net/post111523/

ICARE Social Media Post November 2023

Inherited Genes Associated With Aggressive Types Of Prostate Cancer

A new study found that inherited BRCA2, ATM, and NBN genes were most strongly associated with aggressive or metastatic prostate cancer. Learn more at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2809874 Reference: Darst, et al. JAMA Oncol. 2023. PMID: 37733366.

Permanent link to this article: https://inheritedcancer.net/post110923/

ICARE Social Media Post November 2023

Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing

Language barriers should never prevent people from accessing essential information in the field of healthcare. To fill the gap caused by the lack of Spanish-speaking genetic counselors, our team developed a web-based genetic education tool ๐Ÿงฌ A study among 41 Spanish-speaking found that viewing the tool significantly increased knowledge and feeling informed and empowered to …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110123/

ICARE Social Media Post November 2023

Piloting a Spanish-Language Web-Based Tool for Hereditary Cancer Genetic Testing

Las barreras del idioma nunca deberรญan impedir que las personas accedan a informaciรณn esencial en el campo de la atenciรณn de salud. Para llenar el vacรญo causado por la falta de asesores genรฉticos que hablan espaรฑol, nuestro equipo desarrollรณ una herramienta de educaciรณn genรฉtica basada en la web. Un estudio entre 41 hispanohablantes encontrรณ que …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110123_1/

ICARE Social Media Post October 2023

Pancreatic Acinar Cell Carcinoma

Permanent link to this article: https://inheritedcancer.net/post102923/

ICARE Social Media Post October 2023

Triple-negative breast cancers across populations

Triple-negative breast cancers, which do not have estrogen, progesterone, or HER2 receptors, can be more serious and difficult to treat. Inherited breast cancer gene mutations, like BRCA1/2, are more common among this type of breast cancer – which is why it is important for those with triple-negative breast cancer to consider getting genetic testing that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102223/

ICARE Social Media Post October 2023

BRCA1/2 Carriers with Risk-Reducing Salpingo-Oophorectomy: Cancer Worry?

A study found that the majority of BRCA1/2 carriers who underwent risk-reducing salpingo-oophorectomy have declining cancer worry. However, a subset had concerns – these individuals are important to identify and try to offer additional support to. Use the following link to learn more: https://bit.ly/3qflyig Reference: van Bommel, et al. Support Care Cancer. 2022;30(4):3409-3418. PMID: 34997316.

Permanent link to this article: https://inheritedcancer.net/post102023/

ICARE Social Media Post October 2023

Navigating BRCA1/2 Choices

A recent randomized controlled trial among 107 BRCA1/2 carriers, which included ICARE participants, evaluated the effectiveness of a behavioral phone intervention delivered by genetic counselors on the uptake of risk-reducing salpingo-oophorectomy. Women who received the intervention had significantly lower decisional conflict and higher knowledge after one year, and at the two year mark, nearly 54% …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101223/

ICARE Social Media Post October 2023

BRCA2 & Melanoma Risk

Are BRCA2 carriers at higher risk for developing melanoma? As featured in our Fall 2023 newsletter, at present, we are not sure because results from different studies have been inconsistent. For instance, one study among 173 families with a BRCA2 mutation found a 2.6-fold risk of developing melanoma; however, another study of 139 Dutch families …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100623/

ICARE Newsletter Fall 2023

Community Spotlight

My paternal grandparents were my heroes. Wise beyond their time, they relished teaching our familythat knowledge is power, health is everything, and love is unconditional. Back then, Prevention healthmagazine and vitamin supplements filled their mailbox and 1960โ€™s exercise guru Jack LaLane, and health foodadvocate Euell Gibbons, beckoned new followers from a talking picture box in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-community-spotlight/

ICARE Newsletter Fall 2023

Ask the Expert

This question was addressed by Kelly Taylor, MS, LCGC, a licensed and certified genetic counselor with expertise inresearch genetics and hereditary cancers at the Vanderbilt Hereditary Cancer Clinic. If you have a question you wouldlike addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: I have Lynch Syndrome and an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-ask-the-expert/

ICARE Newsletter Fall 2023

BRCA-associated Prostate Cancers

On April 28th, 2023, the FDA approved olaparib plus abiraterone acetate for first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-brca-associated-prostate-cancers/

ICARE Newsletter Fall 2023

Healthcare Delivery

A recent study, based on ICARE participants, found that getting care according to guidelines depends on what the healthcare provider recommends, as well as how much trust the patient has in their care. This study shows us how important it is to find ways to improve knowledge among healthcare providers and trust in care among …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-healthcare-delivery/

ICARE Newsletter Fall 2023

Germline EGFR Mutations and Familial Lung Cancer

A study, in which our Vanderbilt colleagues Georgia Wiesner, MD, MS (geneticist) and Kelly Taylor, MS, LCGC (genetic counselor) participated, was recently published about the inherited T790M EGFR mutation. Mutations in this gene lead to a higher risk or lung cancer and were found to be more common in the Southeast United States where there …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-germline-egfr-mutations-and-familial-lung-cancer/

ICARE Newsletter Fall 2023

Genes Associated with Aggressive Prostate Cancer

A new study of almost 18,000 men with prostate cancer showed that inherited mutations in the BRCA2, ATM, and NBN genes were strongly associated with aggressive prostate cancer. Less strong associations were seen for inherited mutations in the MSH2, XRCC2, and MRE11A genes. The findings of this study suggest that knowing about inherited genes that …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-genes-associated-with-aggressive-prostate-cancer/

ICARE Newsletter Fall 2023

Are BRCA2 Carriers at Higher Risk for Melanoma?

At present, we are not sure because results from different studies have been inconsistent (1). For instance, one study among 173 families with a BRCA2 mutation found a 2.6-fold risk of developing melanoma (2); however, another study of 139 Dutch families with a BRCA2 mutation revealed a lower than general population risk for melanoma (3). …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-are-brca2-carriers-at-higher-risk-for-melanoma/

ICARE Newsletter Fall 2023

Fertility Treatment in BRCA Carriers: Breast Cancer Risk

A recent study among female BRCA carriers showed risk of breast cancer was not significantly raised through fertility treatment, which is reassuring. There remains a need to further study this question in more detail, for associations with breast cancers across different breast cancer subtypes, including breast cancers that are hormone-related and breast cancers that are …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-fertility-treatment-in-brca-carriers-breast-cancer-risk/

ICARE Newsletter Fall 2023

Newly released ACMG Clinical Practice Resource on CHEK2 Developed Through a Group of Worldwide Experts!

A person with a pathogenic variant in the CHEK2 gene may be at an increased risk for developing breast and other cancers. This ACMG Clinical Practice Resource, published in ACMGโ€™s flagship journal, Genetics in Medicine, provides valuable information for healthcare providers caring for individuals with pathogenic variants in the CHEK2gene. This new ACMG Practice Resource …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-newly-released-acmg-clinical-practice-resource-on-chek2-developed-through-a-group-of-worldwide-experts/

ICARE Newsletter Fall 2023

Tamoxifen and Breast Cancer Risk in Women with a BRCA1 or BRCA2 Mutation

In a study of female BRCA carriers, including ICARE participants, those that used tamoxifen and/or raloxifenewere compared to those that did not. After an average follow-up time of almost 7 years, 10.9% of those in the tamoxifen/raloxifene group were diagnosed with breast cancer, compared to 14.3% in the group that did not use thesedrugs. This …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-tamoxifen-and-breast-cancer-risk-in-women-with-a-brca1-or-brca2-mutation/

ICARE Newsletter Fall 2023

BRCA1 and BRCA2 Carriers: Cancer Risks with Oral Contraceptive Use (UK)

Among female BRCA1 and BRCA2 carriers, a recent study found that oral contraceptive use is associated with:โ€บ Raised risk of breast cancer, but only in those using for over 5 years (relative risk: 1.25)โ€บ Lower risk of ovarian cancer (nearly cut in half) Park, et al. Carcinogenesis. 2022;43(3):231-242. PMID:

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-brca1-and-brca2-carriers-cancer-risks-with-oral-contraceptive-use-uk/

ICARE Newsletter Fall 2023

Recommendations for Inherited Ovarian Cancer Genes: United Kingdom (UK)

Through consensus, management recommendations were developed in the UK for females with pathogenic variants inthe following inherited ovarian cancer genes: RAD51C, RAD51D, BRIP1, and PALB2. Hanson, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032. Social media post September 26th, 2023.Available at https://tinyurl.com/post9262023.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-recommendations-for-inherited-ovarian-cancer-genes-united-kingdom-uk/

ICARE Newsletter Fall 2023

Mammograms: New U.S. Preventive Services Task Force (USPSTF) Recommendations

On May 9th, 2023, the USPSTF published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years, for those at average (population) risk forbreast cancer. This change in recommendation is due to recent troubling trends, including an increase in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-mammograms-new-u-s-preventive-services-task-force-uspstf-recommendations/

ICARE Newsletter Fall 2023

National Comprehensive Cancer Network (NCCN) Guidelines Updates

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic CancerReleased August 28th, 2023 (V1.2024) โ€บ Transgender, Non-Binary, and Gender Diverse Individuals: NEW section on care (Page 63-66, TNBGD-1 to 4)โ€บ Li-Fraumeni Syndrome: Significant updates to content (risks and care) (Pages 57-60, LIFR-A): Table added …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2023-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Social Media Post October 2023

What Are Established Cancer Genes?

There are many different inherited breast cancer genes, and different genes lead to different levels of breast cancer risk:

Permanent link to this article: https://inheritedcancer.net/post100423/

ICARE Social Media Post August 2023

ย  BRCA1/2 Outcomes: Metastatic Breast Cancer ย 

According to a recent study, germline BRCA1/2 status did not affect prognosis. However, outcomes differed by immunohistochemistry (IHC) subtype as follows: Use the link in bio to learn more! Reference: Mailliez, et al. Int J Cancer. 2023;152(5):921-931. PMID: 36161271.

Permanent link to this article: https://inheritedcancer.net/post83032/

ICARE Social Media Post August 2023

ย Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

ย 

The National Comprehensive Cancer Network (NCCN) just released updated Genetic/Familial Breast, Ovarian, and Pancreatic Cancer guidelines on August 28th, 2023, which included: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post82923/

ICARE Social Media Post August 2023

ย FDA Approval Post – Approves Niraparibย 

ย 

A critical step forward in cancer care! The FDA has approved the use of niraparib and abiraterone acetate with prednisone in treating patients with BRCA-mutated castration-resistant prostate cancer. The green light comes backed by the robust efficacy data from the MAGNITUDE trial. Read more about the FDA approval at โ https://tinyurl.com/dzdvtm9m Learn more about the MAGNITUDE …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post82423/

ICARE Social Media Post August 2023

Cancer Risks: Inherited CDH1 Mutations ย 

A recent study found that inherited CDH1 mutations: These findings support expansion of lobular breast cancer-centered criteria. Use this link to learn more: http://bit.ly/3DJa7Cs Reference: Garcia-Pelaez, et al. Lancet Oncol. 2023 Jan;24(1):91-106. PMID: 36436516.

Permanent link to this article: https://inheritedcancer.net/post82223/

ICARE Social Media Post August 2023

UK Recommendations for: Inherited Ovarian Cancer Genes

Through consensus, management recommendations were developed in the UK for females with pathogenic variants in the following inherited ovarian cancer genes: Learn more at the link in bio! Reference: Hanson H, et al. J Med Genet. 2023;60(5):417-429. PMID: 36411032.

Permanent link to this article: https://inheritedcancer.net/post81823/

ICARE Social Media Post August 2023

Fertility Treatment in BRCA Carriers: Breast Cancer Risk

A study found that fertility treatment did not significantly raise the risk of breast cancer, which is reassuring. However, further research is required with regard to: Use the link in bio to learn more! Reference: Liu et al. Front Endocrinol (Lausanne). 2022;13:986477. PMID: 36176466.

Permanent link to this article: https://inheritedcancer.net/post81123/

ICARE Social Media Post August 2023

New Article – Cancer Risk Management

A recent study, which ๐—ถ๐—ป๐—ฐ๐—น๐˜‚๐—ฑ๐—ฒ๐—ฑ ๐—œ๐—–๐—”๐—ฅ๐—˜ ๐—ฝ๐—ฎ๐—ฟ๐˜๐—ถ๐—ฐ๐—ถ๐—ฝ๐—ฎ๐—ป๐˜๐˜€, found that getting care according to guidelines depends on: Therefore, we need ways to improve knowledge among healthcare providers and trust in care among patients! Use this link to learn more: https://tinyurl.com/n26m4zys Reference: Dean, et al. Genet Med. 2023;100945. PMID: 37515473.

Permanent link to this article: https://inheritedcancer.net/post80723/

ICARE Social Media Post July 2023

ACMG Clinical Practice Resource on CHEK2

Check out the newly released ACMG Clinical Practice Resource on CHEK2 developed through a group of worldwide experts! ๐Ÿ‘‡https://tinyurl.com/bp8esxsf Read the ACMG press release at ๐Ÿ‘‡https://tinyurl.com/yvammhzt

Permanent link to this article: https://inheritedcancer.net/post72623/

ICARE Social Media Post July 2023

Inherited Cancer Genes in Children: BRCA1/2, PALB2, ATM, CHEK2 , Lynch Genes

Recent study findings suggest that BRCA1/2, PALB2, ATM, CHEK2, and the Lynch Syndrome genes might confer reduced penetrance cancer risk among children. However, there are no adjustments to management or testing recommendations based on the level of risk (i.e., normally do not test children for conditions that primarily increase the risk of cancer in adulthood). …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post72123/

ICARE Social Media Post July 2023

BRCA1/2 carriers: Risks with Oral Contraceptives Use

Among female BRCA1 and BRCA2 carriers, a recent study found that oral contraceptive use is associated with an increased risk of breast cancer, but only among users who have been using them for more than five years, while ovarian cancer risk was nearly cut in half. Use the link in bio to learn more! Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70623/

ICARE Social Media Post July 2023

CDKN2A Mutations: Pancreatic Cancer Screening over 20 years of follow up

A study among CDKN2A carriers assessing the yield and outcomes of 20 years of pancreatic cancer screening found: These results highlight the potential importance of pancreatic cancer screening among CDKN2A carriers. Currently, NCCN guidelines recommend annual pancreatic cancer screening starting at age 40, regardless of family history. Use the link in bio to learn more! …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post70223/

ICARE Social Media Post June 2023

Breast Cancer Risk Model: Predicting Risk over 10-year period

A new study found that mammographic features (density, microcalcifications, masses, and left-right breast asymmetries) predicted risks better than traditional lifestyle/familial risk-based risk models over a 10-year period. โ Use this link to learn more: https://bit.ly/443GDLd Reference: Eriksson et al. J Clin Oncol. 2023;JCO2201564. PMID: 36930854.

Permanent link to this article: https://inheritedcancer.net/post62823/

ICARE Social Media Post June 2023

Li-Fraumeni Syndrome/TP53 mutations

A recent study found that, regardless of a prior cancer diagnosis, there was no increased cancer worry after 1 year of full-body MRI surveillance in TP53 carriers. Further research is needed to evaluate these issues further. Use the link in bio to read the full article! Reference: Omran, et al. Cancer. 2023;129(6):946-955. PMID: 36601958.

Permanent link to this article: https://inheritedcancer.net/post62123/

ICARE Social Media Post June 2023

Should Black women be screened earlier?

A recent study found that Black women had the highest rate of breast cancer deaths in their 40s, compared to White women and women of other races and ethnicities. โ Use this link to learn more: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2803948?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=041923 Reference: Chen T, et al. JAMA Netw Open. 2023;6(4):e238893. PMID: 37074714.

Permanent link to this article: https://inheritedcancer.net/post62023/

ICARE Social Media Post June 2023

FDA Advisory Committee Recommendation: Olaparib for Prostate Cancer Treatment

Olaparib plus abiraterone acetate is recommended as the first line treatment for metastatic castration-resistant prostate cancer, but only in patients whose tumors have BRCA mutations. Although a broad indication for the combination therapy was desired, concerns about the trial design were raised, and the phase III results did not explicitly show that patients without a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post61623/

ICARE Social Media Post June 2023

Lynch Syndrome: Screening for Sebaceous Carcinomas

Permanent link to this article: https://inheritedcancer.net/post62223/

ICARE Social Media Post June 2023

Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Colorectal Version 1.2023

The National Comprehensive Cancer Network (NCCN) just released updated colorectal cancer guidelines which includes: You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf

Permanent link to this article: https://inheritedcancer.net/post60823/

ICARE Social Media Post June 2023

Inherited Gene Mutation in Those with Multiple Primary Cancers

Among patients with multiple primary cancers, the proportion with inherited cancer gene mutations increased with the number of primary cancers:โ€ข 2 cancers: 13.1%โ€ข 3 cancers: 15.9%โ€ข 4+ cancers: 18.0% Many of the double primaries, such as those of the breast, ovary, colorectum, and endometrium, occurred in women who would already be eligible for genetic testing. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60723/

ICARE Social Media Post June 2023

June 4th: National Cancer Survivor’s Day

Today is National Cancer Survivors Day! Learn how you can support cancer survivors by visiting the American Association for Cancer Research (AACR) website ๐Ÿ‘‡https://www.aacr.org/patients-caregivers/awareness-months/national-cancer-survivor-month/

Permanent link to this article: https://inheritedcancer.net/post60523-2/

ICARE Social Media Post June 2023

VUS Results: Rates of Reclassification in Inherited Cancer Genes

In a multicenter study evaluating reclassifications of variant of uncertain significance (VUS) results in breast, ovarian, and colorectal cancer susceptibility genes, it was discovered that of 3261 VUS results, 8.1% were reclassified. Of all the reclassified VUS results, 11.3% resulted in clinically actionable findings, and 4.6% led to changes in clinical management. The reclassification rates …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60523/

ICARE Social Media Post May 2023

Cancer Care: Transgender and Gender-Diverse Persons

Did you know that transgender and gender-diverse persons face unique challenges that can influence cancer risk and outcomes? For instance, these individuals face barriers to healthcare access and inequities in treatment, with healthcare providers lacking knowledge about the health needs of this population. Solutions are needed to offer the best care for these individuals. Use …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52223/

ICARE Social Media Post May 2023

Women’s Health Week

In honor of National Women’s Health Week from May 14th to May 20th, we would like to encourage you to speak with your healthcare provider to make sure you are up-to-date on your cancer screenings, such as mammograms and colonoscopies, to help prevent cancer or find it early when it is easier to treat. Spread …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51523/

ICARE Social Media Post May 2023

ATM breast cancer risks: High Risk c.7271T>G mutation

According to a recent study, while there was a reported 2-fold risk for breast cancer overall among ATM carriers, those with the c.7271T>G mutation had the highest risk. Use the link to learn more: https://bit.ly/40bKovj Reference: Hall et al. Cancer Prev Res (Phila). 2021;14(4):433-440. PMID: 33509806.

Permanent link to this article: https://inheritedcancer.net/post51123/

ICARE Social Media Post May 2023

USPSTF New Recommendation: Mammograms Start at Age 40

Yesterday the United States Preventive Services Task Force (USPSTF) published a new draft recommendation for all cisgender women and those assigned female sex at birth to do mammograms from ages 40 to 74, every two years. This change in recommendation is due to recent troubling trends, including an increase in the number of cancers diagnosed …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51023/

ICARE Social Media Post May 2023

Lynch Syndrome: Skin Neoplasms

According to a recent study among individuals with Lynch Syndrome: Use the link in bio to learn more! Reference: Zhong et al. J Am Acad Dermatol. 2023;S0190-9622(23)00173-1. PMID: 36773823.

Permanent link to this article: https://inheritedcancer.net/post50623/

ICARE Social Media Post May 2023

PARP Inhibitors for Metastatic Prostate Cancer: Talazoparib

A study that compared a PARP inhibitor (talazoparib) to the standard of care (an androgen receptor inhibitor) in metastatic castration-resistant prostate cancer found that it improved progression-free survival regardless of BRCA mutation status. However, the benefit was greatest in males with a BRCA or other DNA repair gene mutation. Read the full article at this …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post50823/

ICARE Social Media Post April 2023

Cancer Risks in Older Females with a BRCA Mutation

A recent study among over 2200 females (aged 50-75) with BRCA mutations, including ICARE participants, found 379 diagnosed cancers with breast and ovarian cancer being the most common cancers observed. Overall cancer risks were 49% in BRCA1 carriers and 43% in BRCA2 carriers, and cancer risks dropped to 9% among those who had preventative removal …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42823/


ICARE Social Media Post April 2023

Prostate Cancer in Black Men: New Genetic Variants to Explain Higher Risks

Researchers identified 9 new genetic variants that may increase the risk of developing prostate cancer. This study highlights the importance of studying diverse populations. Read the full article at this link: https://www.sciencedirect.com/science/article/abs/pii/S0302283823025617 โ Reference:Chen et al. Eur Urol. 2023;S0302-2838(23)02561-7. PMID: 36872133.

Permanent link to this article: https://inheritedcancer.net/post42223/


ICARE Social Media Post April 2023

New study for BRCA1, BRCA2 , or PALB2 carriers with stage 1-3 breast cancer

An open study for BRCA1, BRCA2, or PALB2 carriers with stage 1-3 breast cancer is currently recruiting! Learn more about the study by visiting https://vanderbilt.trialstoday.org/trial/NCT04584255

Permanent link to this article: https://inheritedcancer.net/post42123/


ICARE Social Media Post April 2023

PARP Inhibitors for Metastatic Prostate Cancer: Niraparib

A study that evaluated a PARP inhibitor (niraparib) in males with metastatic prostate cancer found that those with a BRCA1 or BRCA2 mutation lived longer on average than those who did not have a BRCA mutation. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35131040/โ Reference:Smith et al. Lancet Oncol. 2022;23(3):362-373. PMID: 35131040.

Permanent link to this article: https://inheritedcancer.net/post42023/

ICARE Social Media Post April 2023

Applying the Framework for Interventions to Increase Family Communication

A new study ๐—ฏ๐˜† ๐—ผ๐˜‚๐—ฟ ๐˜๐—ฒ๐—ฎ๐—บ used the Framework for Developing and Evaluating Complex Interventions (FDECI) to evaluate an intervention to improve family communication of positive genetic test results for inherited cancer. The first FDECI phases were beneficial for improving the intervention and planning for continual effectiveness and future implementation phases. Use the link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post41023/

ICARE Newsletter Spring 2023

Community Spotlight

In 1997 when I was a junior in college, my mom called to let me know that my father had been diagnosed with prostate cancer. Luckily for him, Prostate Specific Antigen (PSA) testing had recently started which resulted in early detection and subsequent prostatectomy. Due to his diagnosis and knowing prostate cancer is an inherited …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023span-stylecolor-56b0e4community-spotlight/

ICARE Newsletter Spring 2023

Ask the Expert

The below question was addressed by Ben Ho Park, MD, PhD, who is the Director of the Vanderbilt-Ingram Cancer Center and a Professor of Medicine in the Division of Hematology and Oncology. If you have a question you would like addressed, please email the ICARE team at ICARE@vumc.org for consideration in future newsletters. Q: As …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023ask-the-expert/

ICARE Newsletter Spring 2023

Prostate Cancer Treatment Updates

A study to test niraparib (a PARP inhibitor) in males with metastatic prostate cancer showed that those with an inherited BRCA1 or BRCA2 (BRCA) mutation lived longer on average compared to those without a BRCA mutation. Side effects from niraparib were similar to those previously reported with PARP inhibitors.1 Another PARP inhibitor trial tested an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023prostate-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Treatment Updates

Findings from a Phase II study to evaluate the use of talazoparib (a PARP inhibitor) in individuals with advanced PALB2-mutation breast cancer showed that it appeared effective in certain patients and appeared safe (with similar adverse events as those previously reported with this drug).1 There are several Phase II trials to evaluate PARP inhibitors in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-treatment-updates/

ICARE Newsletter Spring 2023
Breast Cancer Screening in Male BRCA1/2 Carriers

Generally, males with breast cancer present with advanced stage disease, thought to be due to a lack of screening. While data to determine performance of breast screening through mammograms for males at inherited risk is limited, recent studies suggest that the detection rate is similar or better than for females at general population risk.1,2,3 In …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-breast-cancer-screening-in-male-brca1-2-carriers/

ICARE Newsletter Spring 2023
Lynch Syndrome: Colorectal Cancer Risks Revisited

While there are higher cancer risks in BRCA mutation carriers starting in the mid-20s, a recent study focused on studying cancer risks in older females aged 50-75. Of the over 2000 females in the study, which included ICARE participants, 379 cancers were found between age 50 to 75 with risks of 49% in BRCA1 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-lynch-syndrome-colorectal-cancer-risks-revisited/

ICARE Newsletter Spring 2023

Lynch Syndrome: Colorectal Cancer Risks Revisited

A study of 381 individuals with Lynch Syndrome in New Zealand (98 with Lynch Syndrome-associated variants in MLH1, 159 in MSH2, 103 in MSH6, and 21 in PMS2) found that risks for colorectal cancer were lower in MSH6 and PMS2 carriers, suggesting that it might be possible to spread out colonoscopy intervals for these individuals.1 …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023/

ICARE Newsletter Spring 2023

Inherited Breast Cancer: Contralateral Breast Cancer Risks

While higher risks for contralateral breast cancer (CBC) have been known for BRCA1 and BRCA2, a newly published study demonstrated that the risk of CBC is also higher for female PALB2 and CHEK2 carriers; however, no elevated risks were found for ATM carriers (Table 1).1 This information is important to study, as it may be …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-inherited-breast-cancer-contralateral-breast-cancer-risks/

ICARE Newsletter Spring 2023

Melanoma Risk in Li-Fraumeni Syndrome

A recently published cohort study of 483 individuals with Li-Fraumeni Syndrome (LFS) identified 113 skin cancers. The cumulative incidence of a diagnosis of any skin cancer was 36.3% by the age of 70. Specifically for melanoma, the median age at diagnosis was 42 with a 7-fold increased incidence (SIR 7.28, 95% CI 4.50-11.13) compared with …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-melanoma-risk-in-li-fraumeni-syndrome/

ICARE Newsletter Spring 2023

National Comprehensive Cancer Network (NCCN) Guidelines Updates

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, PancreaticJanuary 10th, 2023 (Version 2.2023) focused on male BRCA carriers:โ€บ Consider annual mammograms (particularly in BRCA2 carriers) starting at age 50 or 10 years before the earliest male breast cancer in the family (whichever comes first)February 13th, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2023-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Social Media Post March 2023

Treatment for PALB2-associated breast cancer with Talazoparib

According to a recent Phase II study, Talazoparib may benefit patients with PALB2-associated breast cancer. Findings showed that Talazoparib appeared effective and safe in certain patients with advanced disease. Read the full article at this link: https://www.nature.com/articles/s43018-022-00439-1 Reference: Gruber et al. Nat Cancer. 2022;3(10):1181-1191. PMID: 36253484.

Permanent link to this article: https://inheritedcancer.net/post32723/

ICARE Social Media Post March 2023

New Model: To identify those at high risk for Endometrial (Uterine) Cancer

Did you know endometrial cancer is the 4th most common cancer among females? Currently, clinical practice guidelines do not recommend endometrial cancer screening in the general population. A new risk prediction model was recently developed to identify those at high risk for endometrial (uterine) cancer to determine who could benefit from cancer screenings and risk-reducing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post32623/

ICARE Social Media Post March 2023

Inherited Cancer Testing: Pheochromocytoma & Paraganglioma

Because of the high frequency of mutations found in individuals with pheochromocytoma and paraganglioma, these individuals are advised to consider genetic testing for inherited cancer.Use this link to learn more: โ https://pubmed.ncbi.nlm.nih.gov/35976622/ Reference: Yip, et al. JAMA Surg. 2022;157 (10):870-877. PMID: 35976622

Permanent link to this article: https://inheritedcancer.net/post32223/

ICARE Social Media Post March 2023

Metachronous Colorectal Cancer in Lynch Syndrome

Findings from a recent study: Risk factors for metachronous colorectal cancer included a history of colorectal polyps and having an MLH1 or MSH2 mutation, while protective factors included female sex and extended surgical resection. This highlights the importance of genetic testing and counseling for Lynch syndrome prior to surgery, which can influence surgical strategy and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31923/

ICARE Social Media Post March 2023

Colorectal Cancer Risks: Lynch Syndrome

A study on colorectal cancer risks in Lynch Syndrome patients found that:โ€ข Colorectal cancer risks were lower in MSH6 and PMS2 carriersโ€ข Colonoscopy intervals for these individuals could be longerโ€ข Incomplete polyp removal may be responsible for 1/3 of surveillance-detected colorectal cancers Read the full article with the link in bio! Reference: Lamba, et al. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31323/

ICARE Social Media Post March 2023

New gene alert: MBD4

A new study shows germline MBD4 mutations cause an autosomal recessive tumor predisposing syndrome associated with: This highlights the importance of including MBD4 in genetic testing for polyposis and multi-tumor phenotypes to improve disease management. Use the link in bio to learn more! Reference: Palles, et al. Am J Hum Genet. 2022;109(5):953-960. PMID: 35460607.

Permanent link to this article: https://inheritedcancer.net/post31223/

ICARE Social Media Post March 2023

BGREAT December 2022 Newsletter

Check out the latest edition of our B-GREAT newsletter for updates about inherited cancers in the context of racial inequalities in healthcare. You can read the newsletter by visiting ๐Ÿ‘‡https://bgreatinitiative.inheritedcancer.net/wp-content/uploads/BGREAT-December-2022-Newsletter.pdf Please feel free to share with family members, friends, and/or your healthcare providers.

Permanent link to this article: https://inheritedcancer.net/post30623/

ICARE Social Media Post March 2023

Melanoma in TP53 /Li-Fraumeni Syndrome

A new study found a 7-fold increased incidence of melanoma in individuals with TP53/Li-Fraumeni Syndrome compared with the general population:โ€ข Average age was 42โ€ข Risk to age 40 was 2.8%โ€ข Risk to age 60 was 7.8%โ€ข Risk to age 70 was 14.9% Learn more at the link below!https://pubmed.ncbi.nlm.nih.gov/35183552/ Reference: Hatton, et al. J Invest Dermatol. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30723/

ICARE Social Media Post February 2023

Why is learning about inherited cancer important to guide care?

Why have genetic testing? Genetic testing for inherited cancer can help guide care, including:โ€ข Cancer treatment plans, such as chemotherapy, drugs, surgery, and radiationโ€ข Cancer screening and prevention Sharing genetic test results can also help family members understand their cancer risks.โ 

Permanent link to this article: https://inheritedcancer.net/post22423/

ICARE Social Media Post February 2023

ATM Gene and Breast Cancer Risk for: c.7570G>C Mutation

While ATM mutations are generally associated with a 25-30% lifetime risk for breast cancer, emerging information suggests that the risk in those with a c.7570G>C mutation may be higher. Once confirmed, this information may be important to guide cancer screening and risk-reducing surgery decisions. Use this link to learn more: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34305

Permanent link to this article: https://inheritedcancer.net/post40623/

ICARE Newsletter Spring 2022ย 

ย Reducing Hereditary Cancer Act of 2021ย 

On February 16th, 2022, the Reducing Hereditary Cancer Act (S.3656) was introduced to the U.S. Senate with the goal of ensuring Medicare beneficiaries have coverage for potentially life-saving inherited cancer genetic counseling and testing as well as recommended screening and risk-reducing procedures, when medically necessary and appropriate. Currently, Medicare only covers genetic testing for beneficiaries …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-reducing-hereditary-cancer-act-of-2021/

ICARE Newsletter Spring 2022ย 

ย Community Spotlightย 

Genetic testing sounded like a futuristic concept when it originally came to our attention. It sounded something to the likes of cloning. We didnโ€™t really understand what it was and why it was important, but rather thought it sounded like something out of science fiction. Thankfully, our medical providers and genetic counselors stuck with us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-community-spotlight/

ICARE Newsletter Spring 2022ย 

ย Ask the Expertย 

The below question was addressed by ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid. Dr. Pal is a Professor of Genetic Medicine, Ingram Professor of Cancer Research, and the Associate Director for Cancer Health Disparities at VanderbiltIngram Cancer Center. Dr. Reid is an Assistant Professor of Hematology/Oncology at Vanderbilt University Medical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-ask-the-expert/

ICARE Newsletter Spring 2022ย 

ย Inherited Cancer Treatment Updates

Lynch Syndrome Carriers with Advanced Uterine Cancer: Treatment with PembrolizumabWomen with Lynch Syndrome are at high risk for uterine cancer. The type of uterine cancer they develop has the tumorcharacteristic of being ‘MSI-H’. A new study indicated treatment with pembrolizumab (Keytruda) resulted in benefit inpatients with MSI-H advanced uterine cancer. Von Hippel-Lindau Patients: Treatment of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-inherited-cancer-treatment-updates/

ICARE Newsletter Spring 2022ย 

ย  BRCA1/2 Oral Contraceptives and Breast Cancer

A new study found that among BRCA1/2 carriers, oral contraceptive use strongly lowered cancer risk over oneโ€™s lifetime, even though at first, they raise risks of breast, ovarian, and endometrial cancer.Schrijver et al. J Natl Cancer Inst. 2022 Jan. PMID: 35048954. Social media post February 15th, 2022. Available at:https://tinyurl.com/post21522.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-oral-contraceptives-and-breast-cancer/

ICARE Newsletter Spring 2022ย 

ย  BRCA1/2 and Male Cancer Risksย 

A recent international study found that male BRCA1 and BRCA2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. See the below table for the specific risk levels: Li et al. J Clin Oncol. 2022 Jan. PMID: 35077220. Social media …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-brca1-2-and-male-cancer-risks/

ICARE Newsletter Spring 2022ย 

ย Lynch Syndrome and Prostate Cancer ย 

A new study suggests men with certain MSH2 and MSH6 mutations have higher risks of prostate cancer and may be candidates for PSA screening. Bancroft et al. Lancet Oncol. 2021 Nov. PMID: 34678156. Social media postDecember 17th, 2021. Available at: https://tinyurl.com/post121721

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-lynch-syndrome-and-prostate-cancer/

ICARE Newsletter Spring 2022ย 

ย Polygenic Risk Scores and Inherited Breast Cancer Genes: BRCA1/2, PALB2, CHEK2, and ATM ย 

Breast MRIs are advised in women with >20% lifetime risk of breast cancer. A new study showed that breast cancer risks in BRCA1, BRCA2 and PALB2 carriers remained higher than 20%, regardless of whether polygenic risk scores (PRS) were done, suggesting this is of limited help in refining screening. In contrast, PRS downgraded breast cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-polygenic-risk-scores-and-inherited-breast-cancer-genes-brca1-2-palb2-chek2-and-atm/

ICARE Newsletter Spring 2022ย 

ย Li-Fraumeni Syndrome and Cancer Risksย 

A new study reported on differences in the TP53 mutations between patients who met vs those who did not meet Li-Fraumeni Syndrome (LFS) testing criteria. Several variants were identified multiple times in those who did and did not meet LFS clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282. Other variants were exclusively found in those …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-li-fraumeni-syndrome-and-cancer-risks/

ICARE Newsletter Spring 2022ย 

ย CDH1 and Stomach Cancerย 

A recent study of women with hereditary lobular breast cancer due to CDH1 mutations found high rates ofundetected stomach cancer (with signet ring features). The findings suggested that among CDH1 carriers, there werevery high risks for stomach cancer, even when family history of stomach cancer was absent.Gamble et al. JAMA Surg. 2021 Oct. PMID: 34643667. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-cdh1-and-stomach-cancer/

ICARE Newsletter Spring 2022ย 

ย  ATM and Pancreatic Cancer

A new article reported that pancreatic cancer risks are morethan 6-fold higher in individuals with an ATM mutation.Pancreatic cancer risks by age were:โ€บ 1.1% by age 50โ€บ 6.3% by age 70โ€บ 9.5% by age 80Hsu, et al. JAMA Oncol. 2021 Sep. PMID: 34529012. Social media post October 1st, 2021. Available at: https://tinyurl.com/post100121.

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-spring-2022-atm-and-pancreatic-cancer/

ICARE Newsletter Fall 2022ย 

ย Community Spotlightย 

When I was just 8 years old my mother was diagnosed with a very aggressive breast cancer. I didnโ€™t reallyunderstand the concept of cancer at that age, but I knew what was happening was terrible. After manysurgeries and treatments, she passed away 2 years later at the age of 35. There was no hereditary cancertesting …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-community-spotlight/

ICARE Newsletter Fall 2022ย 

ย Ask the Expertย 

The below question was addressed by Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro Intestinal Surgical Oncology at Vanderbilt-Ingram Cancer Center. Dr. Idreesโ€™ research has focused on colorectal cancer, liver metastases, and pancreatic cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-ask-the-expert/

ICARE Newsletter Fall 2022ย 

ย ATM -associated Cancer Risksย 

Female ATM carriers have approximately a 2-fold risk, on average, for developing breast cancer, which was confirmed through two large studies that reported risks (odds ratio) as 2.10 (95% CI, 1.71โ€“2.57)1 and 1.82 (95% CI, 1.46โ€“2.27). Both studies reported an association with ER+ tumors. Another recent study estimated breast cancer risks to be 13% by …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-atm-associated-cancer-risks/

ICARE Newsletter Fall 2022ย 

ย Screening & Treatment Updates: New Modeling Analysis About Breast Cancer Screening in ATM and CHEK2 Carriersย 

Using information from twelve prior population-based studies, a modeling analysis was done to look at when to start mammography and breast MRI in females with inherited mutations in genes including ATM and CHEK2. Overall, findings showed that starting annual MRI screening between age 30 to 35 and mammography at age 40 may lower death from …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-new-modeling-analysis-about-breast-cancer-screening-in-atm-and-chek2-carriers/

ICARE Newsletter Fall 2022ย 

ย Screening & Treatment Updates: Pancreatic Cancerย 

A recent small study suggests that immunotherapy may benefit patients with refractory pancreatic or biliary cancer who have inherited a mutation in the homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Another new study reported that in BRCA1/2 carriers with pancreatic cancer, maintenance treatment with Olaparib may be of benefit. Findings showed that with Olaparib, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-screening-treatment-updates-pancreatic-cancer/

ICARE Newsletter Fall 2022ย 

ย Which Genes Are Confirmed as ‘Inherited Breast Cancer Genes’?ย 

There were two large studies published early last year that evaluated which genes raise risks for breast cancer, including breast cancer patients from many centers worldwide, representing the largest available datasets to look at this question. These efforts were led by the worldwide Breast Cancer Association Consortium (BCAC)1 and the United States-based CARRIERS consortium. The …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-which-genes-are-confirmed-as-inherited-breast-cancer-genes/

ICARE Newsletter Fall 2022ย 

ย Inherited Cancer Genes: New Associationsย 

A new study led by colleagues at Vanderbilt University Medical Center, including our clinical geneticist colleague, Dr. Georgia Wiesner, evaluated 23 hereditary cancer genes and found 19 new gene associations including 7 new associations with cancer and 12 new associations with noncancer diseases. The associations with cancer versus other conditions is included in the table. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-inherited-cancer-genes-new-associations/

ICARE Newsletter Fall 2022ย 

ย  BRCA1/2 Cancer Risk Updates

During preventive surgery to remove the ovaries and fallopian tubes (called a risk-reducing salpingo-oophorectomy orRRSO), a new study found that the detection of tubal intraepithelial carcinoma predicts the risk of later peritonealcancer.1 These findings show the importance of timely RRSO and the need to do a careful pathology exam of the ovaries and fallopian tubes …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-brca1-2-cancer-risk-updates/

ICARE Newsletter Fall 2022ย 

National Comprehensive Cancer Network (NCCN) Guidelines Updatesย 

Check out the full NCCN guidelines by creating a FREE account at www.nccn.org Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic โ€“ Released September 7th, 2022โ€บ Testing eligibility based on personal history of any type of breast cancer in females was updated from age โ‰ค45 to โ‰ค50 making more females with breast cancer eligible for testing …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2022-national-comprehensive-cancer-network-nccn-guidelines-updates/

ICARE Newsletter Fall 2021ย 

Resource Spotlight: National Cancer Institute’s Cancer Genetics PDQย 

ย 

Looking for a place to get the latest curated information about inherited cancers? Look no furtherโ€ฆ Provide evidence-basedsummaries about inheritedcancer genetics for healthprofessionals and patients Summaries updated basedon monthly review ofpublished literature Written and maintained by amultidisciplinary Editorial Board ofexperts in medical genetics, oncology,and related specialties Visit https://tinyurl.com/NCIPDQ and https://www.cancer.gov/publications/pdq/editorial-boards/genetics for more information

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-resource-spotlight-national-cancer-institutes-cancer-genetics-pdq/

ICARE Newsletter Fall 2021ย 

Direct-to-Consumer Tests: Not Reliable to Detect BRCA1/2 Mutationsย 

Researchers reported that single nucleotide polymorphism (SNP) tests, which are used by DTC tests such as 23andMe, are not reliable in identifying the majority of BRCA1/2 mutations or other inherited cancer gene mutations. The SNP test used by many DTC ancestry and DNA companies is designed to detect common traits many people share. However, when …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-direct-to-consumer-tests-not-reliable-to-detect-brca1-2-mutations/

ICARE Newsletter Fall 2021ย 

Reducing Hereditary Cancer Act of 2021 ย 

Under current Medicare guidelines, only those with “signs, symptoms, complaints, or personal histories of disease” meet the criteria for medical services coverage. Thus, genetic testing is only covered for those already diagnosed with cancer, regardless of family history. If someone without cancer has an inherited mutation that increases cancer risk (e.g., BRCA1/2), Medicare may not …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6icare-newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-reducing-heredit/

ICARE Newsletter Fall 2021ย 

Community Spotlight

At the age of 51, my first and only colonoscopy revealed 100 polyps in my colon, rectum, and anuseven though I had no symptoms or family history. I was immediately referred to a Certified GeneticCounselor at Tripler Army Medical Center in Hawaiโ€™i. Germline DNA testing revealed I had attenuatedfamilial adenomatous polyposis (AFAP), due to an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-community-spotlight/

ICARE Newsletter Fall 2021ย 

Ask the Expertย 

ย 

In each newsletter, we give participants the opportunity to have their questions addressed by experts in thefield. This question was addressed by Kerry Schaffer, MD, medical oncologist at Vanderbilt University MedicalCenter with a focus on urological cancers. Q. Is there enough information to consider using PARP inhibitors to treat inherited forms ofprostate cancer? A. Over …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-ask-the-expert/

ICARE Newsletter Fall 2021ย 
>

Polygenic Risk Scores and Breast Cancer Risks: BRCA1/2, PALB2, CHEK2, ATM , and beyond!

A recent study found use of a polygenic risk score (PRS) modified the estimated riskof breast cancer among both carriers and non-carriers of inherited breast cancerpredisposition genes. Taking PRS into account, more than 95% of BRCA1, BRCA2,and PALB2 carriers had greater than 20% lifetime risks of breast cancer. In contrast,among ATM and CHEK2 carriers without …

Continue reading

Permanent link to this article: https://inheritedcancer.net/icare-newsletter-fall-2021-polygenic-risk-scores-and-breast-cancer-risks-brca1-2-palb2-chek2-atm-and-beyond/

ICARE Social Media Post February 2023

Risk for second breast cancer in premenopausal female BRCA1, BRCA2, PALB2 and CHEK2 carriers

Did you know female BRCA1, BRCA2, CHEK2, or PALB2 carriers have much higher risks for contralateral breast cancer?This information is important to guide cancer screening and risk reduction strategies. Use the link in bio to learn more!

Permanent link to this article: https://inheritedcancer.net/post40123/

Newsletter Fall 2021

Inherited Cancer Treatment Updates

Early-stage, high-risk breast cancer in BRCA carriers: Results of the highly awaited phase 3 OlympiA trial showed promising results for EARLY STAGE (i.e., localized Stage 2-3) high-risk breast cancer patients with a BRCA mutation who were treated with a PARP inhibitor (olaparib) in the adjuvant setting (i.e., AFTER surgery).1 Early-stage breast cancer in this trial …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-inherited-cancer-treatment-updates/

Newsletter Fall 2021

Modifying Risks in BRCA Carriers

Breast cancer risks: A risk-reducing salpingo-oophorectomy (i.e., removal of both ovaries and fallopian tubes) in BRCA carriers was associated with a reduced risk of breast cancer within five years after surgery, with evidence of longer-term risk reduction among those with BRCA1 variants.1 Ovarian cancer risks: A new study reported that the use of oral contraceptives …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-modifying-risks-in-brca-carriers/

Newsletter Fall 2021

Breast Cancer Risks Remain High in PALB2 & BRCA

A new study found that lifetime breast cancer risk is 15% or more in female BRCA1, BRCA2, and PALB2 carriers over age 65. This level of risk warrants consideration for continuing breast MRI.1 These results are similar to those of a study that included ICARE participants,2 which reported the risk of developing breast cancer remains …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-breast-cancer-risks-remain-high-in-palb2-brca/

Newsletter Fall 2021

Prostate Cancer and PALB2

A new Polish study based on two specific founder mutations in PALB2 reported that mutations in this gene may predispose to an aggressive, lethal form of prostate cancer.1 The investigators studied PALB2 prostate cancer risks, characteristics, and outcomes in almost 5,500 men with prostate cancer and compared them to over 8,000 cancer-free adults from Poland. …

Continue reading

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-prostate-cancer-and-palb2/

Newsletter Fall 2021

PALB2 : Increasingly Recognized as the Third Most Important Inherited Breast Cancer Gene

In May 2021, a clinical practice resource was released by the American College of Medical Genetics and Genomics (ACMG) from a global team of cancer genetics specialists (see figure) to help guide the care of PALB2 carriers.1 PALB2 is considered the third most important breast cancer risk gene, after BRCA1 and BRCA2, with PALB2 carriers …

Continue reading

Permanent link to this article: https://inheritedcancer.net/div-classboxedspan-stylecolor-whiteh6newsletter-fall-2021-h6-span-divbrcenterh4span-stylecolor-56b0e4-ipalb2-i-increas/

Newsletter Fall 2021

Updates to NCCN Genetic/Familial High-Risk Assessment

Breast, Ovarian, and Pancreatic Guidelines V.1.2022: Released August 11th, 2021 Colorectal Cancer Guidelines V.1.2021: Released May 11th, 2021 Check out the full NCCN guidelines by creating a FREE account at www.nccn.org

Permanent link to this article: https://inheritedcancer.net/newsletter-fall-2021-updates-to-nccn-genetic-familial-high-risk-assessment/

ICARE Social Media Post January 2023

Inherited Breast Cancers Across Populations

Did you know that BRCA1/2 are amongst the most well-studied genes, yet most BRCA1/2 studies have been done in White populations? This means our knowledge about genes and risks comes primarily from White populations. โ€ข Some research suggests that BRCA1/2 gene mutations may be more common in young Black women with breast cancer. โ€ข Even …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423-2/

ICARE Social Media Post January 2023

Updates to NCCN Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic

The National Comprehensive Cancer Network (NCCN) just released updated breast, ovarian, and pancreatic cancer guidelines which included updated breast cancer screening recommendations for male BRCA carriers (particularly male BRCA2 carriers). It is now recommended that male BRCA carriers consider annual mammograms starting at age 50 or 10 years before the earliest male breast cancer in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12423/

ICARE Social Media Post January 2023

New Contralateral Breast Cancer Risk Prediction Model for BRCA1/2 Carriers

A new risk prediction model was developed to assess the risk of contralateral breast cancer in BRCA1/2 carriers. Risks are higher with:โ€ข Younger age at first breast cancerโ€ข Close family member with breast and/or ovarian cancerโ€ข Mutation located near the 3′ region of the gene Risks are lower with:โ€ข Endocrine therapy Use this link in …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post11423/

ICARE Social Media Post January 2023

Why is diversity in genomics studies important?

Did you know that about 80% of genomics data comes from European populations, yet they only make up about 16% of the world population? This bias means Europeans stand to benefit the most, while important associations for other ancestry groups may be missed. Not including diverse populations in genomics research can further WIDEN disparities!

Permanent link to this article: https://inheritedcancer.net/post10823/

ICARE Social Media Post December 2022

Negative or Uninformative Test Results

A new study demonstrates the importance of retesting patients with previously uninformative cancer genetics evaluations, especially in high risk individuals. Read the full article at this link for more info: https://pubmed.ncbi.nlm.nih.gov/34545504/ ๐Ÿ”—โ  Reference: Dettwyler et al. Fam Cancer. 2022; DOI: 10.1007/s10689-021-00276-8. PMID: 34545504

Permanent link to this article: https://inheritedcancer.net/post121322/

ICARE Social Media Post December 2022

Bilateral Mastectomy in BRCA1/2, PALB2, ATM, & CHEK2 Carriers

A recent study including data from ICARE participants found similar rates of bilateral mastectomy across high (BRCA1, BRCA2, PALB2) and moderate (ATM, CHEK2) penetrance genes. The high rates of bilateral mastectomies seen in those with moderate penetrance genes is concerning for overtreatment. Use the link to learn more: https://jamanetwork.com/journals/jamaoncology/fullarticle/2797978?guestAccessKey=fe9a3a20-8623-4feb-a0c5-315ad43a8fcb&utm_source=jps&utm_medium=email&utm_campaign=author_alert-jamanetwork&utm_content=author-author_engagement&utm_term=1m Reference: Reid et al. Receipt of …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post120822/

ICARE Social Media Post December 2022

Cancer Screen Week

This week is Cancer Screen Week! This week we would like to highlight the importance of screening for inherited cancer to help prevent cancer and find it early. Talk to your healthcare provider today about what screenings are best for you.

Permanent link to this article: https://inheritedcancer.net/post120622/

ICARE Social Media Post November 2022

Cancer Risks: CHEK2

A newly published study reports that the type of CHEK2 mutation leads to different cancer risks. Read the full article at this link: https://jamanetwork.com/journals/jamaoncology/fullarticle/2796767 Reference: Bychkovsky BL, et al. JAMA Oncol. 2022 Sep 22;e224071. PMID: 36136322.

Permanent link to this article: https://inheritedcancer.net/post112122-2/

ICARE Social Media Post November 2022

Fall 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kamran Idrees, Chief of the Division of Surgical Oncology & Endocrine Surgery, Associate Professor of Surgery, Ingram Associate Professor of Cancer Research, and Director of Pancreatic and Gastro-Intestinal Surgical …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post111122/

ICARE Social Media Post November 2022

Guidelines for Hereditary Breast Cancer Treatment

The Expert Panel Consensus, chaired by the Society of Surgical Oncology with the American Society of Clinical Oncology and the American Society of Radiation Oncology, published new recommendations for hereditary breast cancer treatment. Learn more at https://pubmed.ncbi.nlm.nih.gov/32898012/ Reference: Corso & Magnoni. Eur J Cancer Prev. 2021;30(4):311-314. PMID: 32898012.

Permanent link to this article: https://inheritedcancer.net/post110822/

ICARE Social Media Post November 2022

ICARE Fall 2022 Newsletter

The ICARE Fall 2022 Newsletter is now available! Check out this latest edition for recent research and clinical updates, a Q&A with Dr. Kamran Idrees from Vanderbilt-Ingram Cancer Center, and an inspiring community spotlight piece. You can read and download a copy of the newsletter at: https://inheritedcancer.net/newsletters/ Please feel free to share with family members, …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post110422/

ICARE Social Media Post October 2022

Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS)

Have you already had genetic testing for inherited cancer and want to get more education and information about what your results mean for you? We provide free education about inherited cancer risk through our Tool for Inherited Cancer Predisposition Counseling and Testing Study (TIPS). Visit https://redcap.link/TIPS and complete our survey. Once completed, we provide:โ€ข an …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post102422/

ICARE Social Media Post October 2022

October 21 – National Mammography Day

National Mammography Day is observed annually on the third Friday of every October. Today acts as reminder to everyone that early detection is the best defense against breast cancer!

Permanent link to this article: https://inheritedcancer.net/post102122/

ICARE Social Media Post October 2022

October 13 Metastatic Breast Cancer Awareness Day

October 13th is Metastatic Breast Cancer Awareness Day. Today is a day to raise awareness about the importance of furthering cancer research.

Permanent link to this article: https://inheritedcancer.net/post101322/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines single post 3

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, genetic testing eligibility based on age at breast cancer diagnosis in females was updated from โ‰ค 45 to โ‰ค 50 making more females with breast cancer eligible for testing regardless of family history …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post101022/

ICARE Social Media Post October 2022

CanRisk Tool

Have you heard of the CanRisk Tool?The CanRisk Tool provides health care professionals a user-friendly resource to carry out breast and ovarian cancer risk predictions. It is the first freely accessible cancer risk prediction program!Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/33335023/ Reference: Carver et al. Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):469-473. PMID: 33335023.

Permanent link to this article: https://inheritedcancer.net/post100722-2/

ICARE Social Media Post October 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 2

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In these new guidelines, the age to start breast MRI screening in female ATM and CHEK2 carriers was updated from age 40 to 30-35 making more females eligible for screening at an earlier age.Check out the new …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post100222/

ICARE Social Media Post October 2022

Ovarian Cancer Risks: Weight Gain in BRCA1/2 Carriers

A study found that adult weight gain is a risk factor for ovarian cancer. This highlights the importance for BRCA1/2 carriers to maintain a healthy weight throughout adulthood.โ Read the full article to learn more! โ https://pubmed.ncbi.nlm.nih.gov/34426412/โ Reference: Kim et al. Cancer Epidemiol Biomarkers Prev. 2021 Nov;30(11):2038-2043. PMID: 34426412.

Permanent link to this article: https://inheritedcancer.net/post100122/

ICARE Social Media Post September 2022

Breast cancer risks: BRCA1/2 carriers with risk reducing salpingo-oophorectomy (RRSO)

Three recent studies found varying results when evaluating breast cancer risk in BRCA1/2 carriers with risk-reducing salpingo-oophorectomy (RRSO). Use these links to learn more: https://pubmed.ncbi.nlm.nih.gov/31948486/ https://pubmed.ncbi.nlm.nih.gov/33630024/ https://pubmed.ncbi.nlm.nih.gov/35216860/

Permanent link to this article: https://inheritedcancer.net/post92722/

ICARE Social Media Post September 2022

Hormonal Replacement Therapy (HRT) in BRCA1 and BRCA2 carriers

A recent study showed hormone replacement therapy (HRT) is reasonable to offer to BRCA1 and BRCA2 carriers who underwent risk-reducing salpingo-oophorectomy (RSSO). Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/32143914/Reference: Mills, et al. Gynecol Oncol; 2020 Jun;157(3):706-710. PMID: 32143914.

Permanent link to this article: https://inheritedcancer.net/post2922/

ICARE Social Media Post September 2022

Bilateral Oophorectomy: Breast Cancer Risks in BRCA1 Carriers

A recent study, including ICARE participants, found preventive removal of the ovaries does not reduce breast cancer risk in BRCA1 carriers. These findings highlight that study bias can influence results.Read the full article at this link: https://pubmed.ncbi.nlm.nih.gov/35477169/โ Reference: Kotsopoulos et al. Cancer Epidemiol Biomarkers Prev. 2022 Jul 1;31(7):1351-1358. PMID: 35477169.

Permanent link to this article: https://inheritedcancer.net/icare-social-media-post-september-2022-bilateral-oophorectomy-breast-cancer-risks-in-brca1-carriers/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines – single post 1

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines. In this new version, a table was added at the end of the guidelines to summarize inherited cancer content across ๐—ฎ๐—น๐—น NCCN guidelines, including live links to the guidelines and sections referenced (see page 54 on the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post92222/

ICARE Social Media Post September 2022
/span>

Risk of Ovarian Cancer In BRCA1/2 Carriers: Oral Contraceptives and Implants

A new study suggests oral contraceptives and implants lower risk of ovarian cancer in BRCA1/2 carriers.Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35063280/Reference: Xia et al. Gynecol Oncol. 2022;164(3):514-521. doi:10.1016/j.ygyno.2022.01.014. PMID: 35063280.

Permanent link to this article: https://inheritedcancer.net/post92122/

ICARE Social Media Post September 2022

ATM: Breast Cancer Risks

A recent study found that even though ATM has been clearly identified as a breast cancer risk gene with an estimated risk of 13% up to age 80, variant-specific penetrance estimates are needed to guide risk management plans for those with pathogenic mutations.Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/35365198/Reference: Renault et al. Breast Cancer …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post91922/

ICARE Social Media Post September 2022

NCCN Familial/Genetic High Risk Assessment: Breast, Ovarian & Pancreatic Guidelines

On September 7th, 2022, the National Comprehensive Cancer Network (NCCN) released new breast, ovarian, and pancreatic cancer guidelines.Check out the new guidelines at:https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91222/

ICARE Social Media Post September 2022

September ICARE Genetics Case Conference

We are excited to announce that our next ICARE genetics case conference, focused on TERT mutations in myeloid malignancies, will be broadly accessible. We are honored to have Mary Armanios, MD as our guest expert for this conference, in which she will provide a featured presentation and case commentary. We encourage you to join us …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post90822/

ICARE Social Media Post August 2022

Nipple sparing mastectomy: BRCA1/2 carriers

According to a recent study, a bilateral prophylactic nipple-sparing mastectomy appears to be at least equally as safe as other types of mastectomy for preventing breast cancer. Read the full article at the link: https://pubmed.ncbi.nlm.nih.gov/34342702/Reference: Stanek et al. Aesthetic Plast Surg. 2022 Apr;46(2):706-711. PMID: 34342702.

Permanent link to this article: https://inheritedcancer.net/post82922/

ICARE Social Media Post August 2022

ATM: Breast Cancer Risks

ATM variants are linked to an increased risk of breast cancer, with the ATM V2424G variant causing the highest risks and ATM D1853V, L546V, and S707P variants being the least predictive.Read the full article here: https://pubmed.ncbi.nlm.nih.gov/33402103/Reference: Moslemi, et al. BMC Cancer. 2021 Jan 5;21(1):27. PMID: 33402103.

Permanent link to this article: https://inheritedcancer.net/post81922/

ICARE Social Media Post August 2022

Ovarian Cancer Risks: Aspirin

A new report found that regular aspirin use was associated with a 13% reduction in ovarian cancer risk. Read the full article at the link: https://ascopubs.org/doi/abs/10.1200/JCO.21.01900Reference: Hurwitz et al. J Clin Oncol. 2022. PMID: 35867953.

Permanent link to this article: https://inheritedcancer.net/post81222/

ICARE Social Media Post August 2022

Pancreatic Cancer Treatment

ย 

A new study reports that maintenance treatment with Olaparib may benefit BRCA1/2 carriers with pancreatic cancer. These findings demonstrated:โ long-term survival was more commontime to subsequent therapy was prolongedRead the full article at the link: https://ascopubs.org/doi/pdf/10.1200/JCO.21.01604โ Reference: Kindler et al. J Clin Oncol. 2022; JCO2101604. PMID: 35834777.

Permanent link to this article: https://inheritedcancer.net/post80522/

ICARE Social Media Post July 2022

Pancreatic Cancer Screening

A recent study found that earlier diagnosis improved survival in people at high risk of pancreatic cancer.High risk was defined based on:family history and/orinherited gene mutation (BRCA1, BRCA2, CDKN2A, Lynch Syndrome genes, PALB2, ATM, and STK11)Read the article at the link: https://ascopost.com/news/june-2022/outcomes-of-pancreas-surveillance-in-the-caps5-study-and-total-caps-cohort/Reference: Dbouk, et al. J Clin Oncol. 2022 Jun 15:JCO2200298. doi: 10.1200/JCO.22.00298. PMID: 35704792.

Permanent link to this article: https://inheritedcancer.net/post72622/

ICARE Social Media Post June 2022

ATM: High and Moderate Risks for Multiple Cancers

A recent study found that pathogenic variants in the Ataxia Telangiectasia Mutated (ATM) gene are associated with multiple cancers. Specifically, moderate-to-high risks for pancreatic, prostate, gastric, and invasive ductal breast cancers, and low-to-moderate risks for ductal carcinoma in situ, male breast cancer, ovarian cancer, colorectal cancer, and melanoma.This provides more data to guide risks and …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post62122/

ICARE Social Media Post June 2022

Refractory Pancreatic or Biliary Cancer

A recent small study suggests that immunotherapy may be beneficial for patients with refractory pancreatic or biliary cancer who have inherited homologous recombination deficiency (HRD) genes, BRCA1, BRCA2, and RAD51C.Check out the full article to learn more at ๐Ÿ‘‡https://jamanetwork.com/journals/jamaoncology/article-abstract/2791557Reference: Terrero et al. JAMA Oncol. 2022 Apr:e220611. doi:10.1001/jamaoncol.2022.0611. PMID: 35446342.

Permanent link to this article: https://inheritedcancer.net/post61322/

ICARE Social Media Post June 2022

Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results

A new study found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a small proportion of pregnant women. However, among those with suspicious findings, the risk of a confirmed malignancy was quite high.Check out the full article athttps://ascopubs.org/doi/full/10.1200/JCO.21.02260Reference: Heesterbeek et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60822/

ICARE Social Media Post June 2022

New Variants Linked to Hereditary Cancer

A new study evaluated 23 hereditary cancer genes and found 19 new gene associations, including 7 new associations with cancer and 12 new associations with non-neoplastic diseases. Specifically, the below genes were found to have an increased risk of disease:APC: benign liver/bile duct tumors, gastritis, and duodenitisATM: stomach cancer and pancreatic cancerBRCA1/2: ovarian cystsCHEK2: leukemia …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post60122/

ICARE Social Media Post May 2022

BRCA Carriers with Risk-Reducing Salpingo-oophorectomy: Risk of Peritoneal Carcinomatosis

A new study found that among BRCA1/2 carriers, the presence of tubal intraepithelial carcinoma during risk-reducing salpingo-oophorectomy (i.e., preventive surgery to remove the ovaries and fallopian tubes) predicts the risk of later peritoneal cancer. These findings demonstrate:the importance of timely risk-reducing removal of the ovaries and fallopian tubesthat it is VERY important to have a …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post52422/

ICARE Social Media Post May 2022

Breast Cancer Genes in Women of African Ancestry

A recent study in women of African ancestry confirmed genes previously identified to have associations with breast cancer risk (BRCA1, BRCA2, PALB2, ATM, TP53, NF1, and CHEK2) and provided new evidence of breast cancer risk for RAD51C and RAD51D, which was identified previously in European ancestry populations.Check out the full article at ๐Ÿ‘‡https://pubmed.ncbi.nlm.nih.gov/35396981/Reference: Dรญaz-Zabala, et …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post51722/

ICARE Social Media Post May 2022

Melanoma Treatment Update

Results from a small study suggest that melanomas in CDKN2A carriers may have better response rates to immunotherapy compared to non-carriers.Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/30291219/Reference: Helgadottir et al. J Med Genet. 2020 May;57(5): 316-321. PMID: 30291219.

Permanent link to this article: https://inheritedcancer.net/post51022/

ICARE Social Media Post May 2022

CDKN2A and Melanoma

Did you know that CDKN2A mutations are found in 35-43% of families with three or more family members with melanoma?Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33945383/Reference: Pissa et al. Acta Oncol. 2021 Jul;60(7):888-896. PMID: 33945383.

Permanent link to this article: https://inheritedcancer.net/post50622/

ICARE Social Media Post April 2022

Spring 2022 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, ICARE Founder, Dr. Tuya Pal, and her oncology colleague, Dr. Sonya Reid, discuss the types of inherited breast cancer and whether having an inherited form of breast cancer affects survival.Check …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42922/

ICARE Social Media Post April 2022

Disparities: PARP Inhibitors & Ovarian Cancer

A recent study found that non-Hispanic Black and Hispanic women are underrepresented in clinical trials evaluating PARP inhibitor use among ovarian cancer patients; therefore, these trials do not accurately represent the ovarian cancer patient population. These findings indicate initiatives to increase diversity in clinical trials are needed. Read the full article for more information ๐Ÿ‘‡https://www.gynecologiconcology-online.net/article/S0090-8258(22)00071-3/fulltext#secst0030Reference: …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post42222/

ICARE Social Media Post April 2022

BRCA1/2 Carriers with Breast Cancer: Olaparib & Survival

A new study found that adjuvant olaparib significantly extended survival in BRCA1/2 carriers with HER2-negative high-risk early-stage breast cancer. Learn more at the following link: https://www.healio.com/news/hematology-oncology/20220323/adjuvant-olaparib-prolongs-survival-for-certain-patients-with-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post41922/

ICARE Social Media Post April 2022

Metastatic Prostate Cancer & Olaparib

Read the full article for more information!https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00017-1/fulltextReference: Thiery-Vuillemin, et al. Lancet Oncol. 2022 Mar;23(3):393-405. PMID: 35157830.

Permanent link to this article: https://inheritedcancer.net/post40822/

ICARE Social Media Post April 2022

Detection of Early-Stage Pancreatic Ductal Adenocarcinoma from Blood Samples

Permanent link to this article: https://inheritedcancer.net/post40522/

ICARE Social Media Post April 2022

Breast Cancer Mortality & MRI Screening: ATM, CHEK2, and PALB2

A new study suggests that annual breast MRI screening may reduce deaths from breast cancer by half in women with ATM, CHEK2 and PALB2 gene mutations. The data suggests starting with annual breast MRIs between the ages of 30 to 35, and adding annual mammograms starting at age 40. Read the full article to learn …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post40122/

ICARE Social Media Post March 2022

BRCA1/2: Asian Breast Cancer Patients

A new study highlights the importance of customizing mutation carrier prediction models in order to improve the accuracy of predicting the likelihood of carrying a BRCA mutation in Asian breast cancer patients.Read the article for more info!https://ascopubs.org/doi/abs/10.1200/JCO.21.01647?cid=DM9826&bid=143994923Reference: Hong Ang et al. J Clin Oncol. 2022 Feb 10;JCO2101647. PMID: 35143328.

Permanent link to this article: https://inheritedcancer.net/post32522/

ICARE Social Media Post March 2022

Breast Cancer: Leading Cause Of Cancer-Associated Death Among Black Women

Did you know breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in the United States? Although Black women are at a lower risk for developing breast cancer, they are 41% more likely to die of breast cancer compared with White women.Future research is needed to reverse course, through …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post31722/

ICARE Social Media Post March 2022

FDA Approves Olaparib for Adjuvant Treatment of High-risk Early Breast Cancer

On March 11th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) for the adjuvant treatment of BRCA1/2 carriers with human epidermal growth factor receptor 2 (HER2)-negative, high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy.Learn more at ๐Ÿ‘‡https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-adjuvant-treatment-high-risk-early-breast-cancer

Permanent link to this article: https://inheritedcancer.net/post31522/

ICARE Social Media Post March 2022

Komen Blog Post: Dr. Pal Interview

Komen Scholar, ICARE Founder and Clinical Geneticist, Dr. Tuya Pal, was recently interviewed for the Komen Blog. In the interview, Dr. Pal discusses the importance of making genetic counseling and testing more accessible in order to help populations who are at high risk for inherited cancer make more informed decisions about their medical care.Read the …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post30922/

ICARE Social Media Post March 2022

Lynch Syndrome: Uterine Cancer Treatment

ย 

A new study indicated treatment with pembrolizumab (Ketruda) resulted in benefit in patients with MSI-H advanced uterine cancer. Read the full article to learn more!https://ascopubs.org/doi/10.1200/JCO.21.01874Reference: O’Malley et al. J Clin Oncol. 2022 Jan 6;JCO2101874. PMID: 34990208.

Permanent link to this article: https://inheritedcancer.net/post30122/

ICARE Social Media Post February 2022

Use of Germline BRCA Testing in Patients With Ovarian Cancer and Commercial Insurance

A recent study found that only about 33% of women with ovarian cancer undergo germline BRCA1/2 testing, despite universal recommendations for such patients to have germline genetic testing. Check out the article for more information!https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2787937?resultClick=3Reference: Cham et al. JAMA Netw Open. 2022 Jan 4;5(1):e2142703. PMID: 35015069.

Permanent link to this article: https://inheritedcancer.net/post22122/

ICARE Social Media Post Month Year

Genetic Testing & Mortality Among Women with Breast or Ovarian Cancer

A recent study found there were BETTER short-term outcomes among women with:โ€ข triple-negative breast cancer and BRCA1 or BRCA2 mutationsโ€ข ovarian cancer and BRCA2, BRIP1, RAD51C, or ATM mutationsThese findings may be reassuring to individuals with inherited gene mutations related to breast and ovarian cancer. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/34373918/Reference: Kurian et al. J …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post21822/

ICARE Social Media Post February 2022

BRCA1/2 Cancer Risks: Oral Contraceptives

A new study found that among BRCA1/2 carriers oral contraceptive use strongly decreases lifetime cancer risk, despite an ๐—ถ๐—ป๐—ถ๐˜๐—ถ๐—ฎ๐—น increase in breast, ovarian, and endometrial cancer risk. Read the full article to learn more!https://pubmed.ncbi.nlm.nih.gov/35048954/Reference: Schrijver et al. J Natl Cancer Inst. 2022 Jan 20;djac004. PMID: 35048954

Permanent link to this article: https://inheritedcancer.net/post21522/

ICARE Social Media Post February 2022

Polygenic Risk Scores: BRCA1, BRCA2, PALB2, CHEK2 & ATM

Permanent link to this article: https://inheritedcancer.net/post20822/

ICARE Social Media Post February 2022

Breast Cancer Characteristics Across Genes

ย 

A new study demonstrated that breast cancer pathology and other clinical features differ by inherited breast cancer gene. Read the full article to learn more!https://jamanetwork.com/journals/jamaoncology/fullarticle/2788577Reference: Breast Cancer Association Consortium. JAMA Oncol. 2022 Jan 27. PMID: 35084436

Permanent link to this article: https://inheritedcancer.net/post20122/

ICARE Social Media Post January 2022

Male Cancer Risks: BRCA1 & BRCA2

A new study found that male BRCA1/2 carriers have a higher risk for breast, pancreatic, and stomach cancer. Additionally, male BRCA2 carriers were found to have higher risks for prostate cancer. Read the full Journal of Clinical Oncology article to learn more!https://ascopubs.org/doi/full/10.1200/JCO.21.02112Reference: Li et al. J Clin Oncol. 2022 Jan 25;JCO2102112. PMID: 35077220.

Permanent link to this article: https://inheritedcancer.net/post12822/

ICARE Social Media Post January 2022

Overview of genetic services delivery for hereditary breast cancer

A recent article by Drs. Sonya Reid, Tuya Pal, and Lucy Spalluto, and Katie Lang, MS, CGC and Anne Weidner, MPH of the ICARE team, has just been published with @SpringerNature in ๐˜‰๐˜ณ๐˜ฆ๐˜ข๐˜ด๐˜ต ๐˜Š๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ ๐˜™๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ ๐˜ข๐˜ฏ๐˜ฅ ๐˜›๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต. This article outlines the importance of genetic services and follow-up care for hereditary breast cancer, as well as …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post12622/

ICARE Social Media Post January 2022

BRCA Breast Cancer Risks After Age 60

A study that included ICARE participants reported the risk of developing breast cancer remains high after age 60 in both BRCA1 and BRCA2 carriers. Read the article to learn more!https://pubmed.ncbi.nlm.nih.gov/33423179/Reference: Stjepanovic et al. Breast Cancer Res Treat. 2021 Jun;187(2):515-523. PMID: 33423179

Permanent link to this article: https://inheritedcancer.net/post12522/

ICARE Social Media Post January 2022

Belzutifan in Von Hippel-Lindau Disease Patients

Belzutifan demonstrated clinical efficacy in patients with renal cell carcinoma who have Von Hippel-Lindau Disease. Learn more by reading the full The New England Journal of Medicine article at ๐Ÿ‘‡https://www.nejm.org/doi/full/10.1056/NEJMoa2103425Reference: Jonasch, et al. N Engl J Med. 2021 Nov 25;385(22):2036-2046. PMID: 34818478.

Permanent link to this article: https://inheritedcancer.net/post12122/

ICARE Social Media Post January 2022

Dr. Pal’s GIM Editorial

ย 

Estimating Polygenetic Risk Scores in non-Europeans through extrapolating from data in European descent populations is not accurate! Diversity in genomic studies is critically needed for both equity and scientific discovery. For more information, read the Genetics in Medicine editorial by ICARE Founder, Dr. Tuya Pal, here ๐Ÿ‘‡https://www.gimjournal.org/article/S1098-3600(21)05396-X/fulltextReference: Pal. Genet Med. 2021 Nov 20;S1098-3600(21)05396-X. PMID: 34906472.

Permanent link to this article: https://inheritedcancer.net/post11822/

ICARE Social Media Post January 2022

Gastric Cancer Risks: CDH1

Read the ๐˜‘๐˜ˆ๐˜”๐˜ˆ ๐˜š๐˜ถ๐˜ณ๐˜จ๐˜ฆ๐˜ณ๐˜บ article to learn morehttps://jamanetwork.com/journals/jamasurgery/article-abstract/2785097Reference: Gamble et al. JAMA Surg. 2021 Oct 13;e215118. PMID: 34643667.

Permanent link to this article: https://inheritedcancer.net/post11122/

ICARE Social Media Post January 2022

Ovarian Cancer: BRCA1/2 Maintenance Olaparib

Read the full article for more details ๐Ÿ‘‡https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00531-3/fulltextReference: Banerjee et al. Lancet Oncol. 2021 Dec;22(12):1721-1731. PMID: 34715071.

Permanent link to this article: https://inheritedcancer.net/post10422/

ICARE Social Media Post December 2021

Fall 2021 Community Spotlight

In every ICARE newsletter we feature a ๐—ฐ๐—ผ๐—บ๐—บ๐˜‚๐—ป๐—ถ๐˜๐˜† ๐˜€๐—ฝ๐—ผ๐˜๐—น๐—ถ๐—ด๐—ต๐˜ to share their experience with inherited cancer. In the latest edition, Dan Dry Dock Shockley, shares his experience with attenuated familial adenomatous polyposis (AFAP). Check out his full story at ๐Ÿ‘‡https://inheritedcancer.net/community-spotlight/

Permanent link to this article: https://inheritedcancer.net/post123021/

ICARE Social Media Post December 2021

Fall 2021 Ask the Expert

In every ICARE newsletter we give our participants the opportunity to have a question addressed by an expert in the field. In the latest edition, Dr. Kerry Schaffer discusses the use of PARP inhibitors to treat inherited forms of prostate cancer.Check out Dr. Schaffer’s full response at ๐Ÿ‘‡https://inheritedcancer.net/newsletters/

Permanent link to this article: https://inheritedcancer.net/post122821/

ICARE Social Media Post December 2021

Breast Cancer Risk Prediction Model for Black Women

ย 

A new breast cancer model has been developed and validated for breast cancer risk prediction, specifically for Black women in the United States. This is in contrast to prior models, which were developed in White women, and used in Black women (which UNDERPREDICTED risks). This is a notable advance as we strive towards health equity …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122321/

ICARE Social Media Post December 2021

Li-Fraumeni Syndrome Cancer Risks

โ€ข Several variants were identified multiple times in those who did and did not meet Li-Fraumeni Syndrome clinical criteria: p.R175, p.G245, p.R248, p.R273, and p.R282โ€ข Other variants were exclusively found in those in the Li-Fraumeni Syndrome group: p.M133T, p.P152L, p.C275Y, p.C275, p.R337C, p.R342, and p.R342Pโ€ข One variant was exclusively found in patients with attenuated Li-Fraumeni …

Continue reading

Permanent link to this article: https://inheritedcancer.net/post122121/

ICARE Social Media Post December 2021

Prostate Cancer Screening: MSH2 & MSH6

A new study suggests men with MSH2 and MSH6 mutations have a higher incidence of prostate cancer, and may be candidates for PSA screening. Read the full article to learn more ๐Ÿ‘‡ https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00522-2/fulltext Reference: Bancroft et al. Lancet Oncol. 2021 Nov;22(11):1618-1631. PMID: 34678156.

Permanent link to this article: https://inheritedcancer.net/post121721/

ICARE Social Media Post December 2021

FDA Approves Belzutifan for Cancers Associated With von Hippel-Lindau Disease

On August 13th, the FDA approved the use of belzutifan (Welireg) for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors not requiring immediate surgery. For more information, check out The ASCO Post article at ๐Ÿ‘‡https://ascopost.com/news/august-2021/fda-approves-belzutifan-for-cancers-associated-with-von-hippel-lindau-disease/?utm_source=TAP-EN-081321&utm_medium=email&utm_term=49cf1c97d48c2cf8231827e3bcb15769

Permanent link to this article: https://inheritedcancer.net/post121021/

ICARE Social Media Post December 2021

FDA Approves PARP Inhibitor (Olaparib) Treatment for some BRCA carriers with Early Stage Breast Cancer

FDA granted priority review to Olaparib for adjuvant treatment of certain patients with high-risk breast cancer. This designation applies to use of the agent by patients with BRCA-mutated, HER2-negative, high-risk early breast cancer who receive chemotherapy before or after surgery. For additional information, visit: https://tinyurl.com/healioFDAapproval

Permanent link to this article: https://inheritedcancer.net/post120621/

ICARE Social Media Post December 2021

The Impact of Subtype and Race on Breast Cancer Survival

A recent article ๐—น๐—ฒ๐—ฑ ๐—ฏ๐˜† ๐——๐—ฟ๐˜€. ๐—ฆ๐—ผ๐—ป๐˜†๐—ฎ ๐—ฅ๐—ฒ๐—ถ๐—ฑ ๐—ฎ๐—ป๐—ฑ ๐—ง๐˜‚๐˜†๐—ฎ ๐—ฃ๐—ฎ๐—น ๐—ผ๐—ณ ๐˜๐—ต๐—ฒ ๐—œ๐—–๐—”๐—ฅ๐—˜ ๐˜๐—ฒ๐—ฎ๐—บ, published in ๐˜‰๐˜ณ๐˜ฆ๐˜ข๐˜ด๐˜ต ๐˜Š๐˜ข๐˜ฏ๐˜ค๐˜ฆ๐˜ณ ๐˜™๐˜ฆ๐˜ด๐˜ฆ๐˜ข๐˜ณ๐˜ค๐˜ฉ ๐˜ข๐˜ฏ๐˜ฅ ๐˜›๐˜ณ๐˜ฆ๐˜ข๐˜ต๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต, outlines the impact of race and molecular subtype on HR+, HER2- breast cancer survival. Check out the full article at https://link.springer.com/content/pdf/10.1007/s10549-021-06342-0.pdf Reference: Reid et al. Breast Cancer Res Treat. 2021 Oct;189(3):845-852. PMID: 34331630.

Permanent link to this article: https://inheritedcancer.net/post120321/

ICARE Social Media Post November 2021

Variation in Colorectal Cancer Risk in Families With Lynch Syndrome

For more information, read the Lancet Oncology article led by The International Mismatch Repair Consortium at the below link ๐Ÿ‘‡https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00189-3/fulltext Reference: International Mismatch Repair Consortium. Lancet Oncol. 2021 Jul;22(7):1014-1022. PMID: 34111421.

Permanent link to this article: https://inheritedcancer.net/post113021/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, view the article at ๐Ÿ‘‡https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djab141/6323231 Reference: Johnson et al. PMID: 34291289.

Permanent link to this article: https://inheritedcancer.net/post110921/

ICARE Social Media Post November 2021

Changes in Racial and Ethnic Disparities in Access to Care and Health Among US Adults at Age 65 Years

For more information, read the full article at: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2782345

Permanent link to this article: https://inheritedcancer.net/post110221/

ICARE Social Media Post October 2021

Pancreatic Cancer Risks: ATM

For more information, read the full article at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2783767 Reference: Hsu, et al. JAMA Oncol. 2021 Sep 16:e213701. PMID: 34529012.

Permanent link to this article: https://inheritedcancer.net/post100121/

ICARE Social Media Post September 2021

USA Today Article: Fighting Cancer with Your Own Family History

Check out the full ๐˜œ๐˜š๐˜ˆ ๐˜›๐˜ฐ๐˜ฅ๐˜ข๐˜บ article, featuring commentary from Dr. Tuya Pal (ICARE Founder), highlighting the importance of PALB2 as an inherited breast cancer gene: https://www.futureofpersonalhealth.com/breast-health/fighting-cancer-with-your-own-family-history/# Additional guidance is available through an impactful PALB2 practice resource recently published through ACMG: https://www.acmg.net/PDFLibrary/41436_2021_1151_OnlinePDF.pdf Reference: Tischkowitz, et al. Genet Med. 2021 Aug;23(8):1416-1423. PMID: 33976419

Permanent link to this article: https://inheritedcancer.net/post92221/

ICARE Social Media Post September 2021

New NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Guidelines (Released August 11th)

The National Comprehensive Cancer Network (NCCN) released new guidelines on August 11th for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. You can check out the full guidelines by creating a FREE account at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf

Permanent link to this article: https://inheritedcancer.net/post91021/

ICARE Social Media Post August 2021

Genetic Risk Assessment for Hereditary Renal Cell Carcinoma

To view the 30 consensus statements, read the full article at: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.33679

Permanent link to this article: https://inheritedcancer.net/post83121/

ICARE Social Media Post August 2021

Breast Cancer Risks: BRCA1/2 & PALB2

For more information, view the article at ๐Ÿ‘‡https://ascopubs.org/doi/full/10.1200/JCO.21.00531